## Page 1

US009289381 B2

(12) United States Patent                   (10) Patent No.:   US 9.289,381 B2
     Elliott et al.                                             (45) Date of Patent:      Mar. 22, 2016

(54)  STABILIZATION AND STORAGE OF                  FOREIGN PATENT DOCUMENTS
    BOLOGICAL PHARMACEUTICAL
    COMPOSITIONS                     WO  WO 2009/O15367 A2       1, 2009
                                                  OTHER PUBLICATIONS
(75)   Inventors: Gloria Elliott, Midland, NC (US);            National Cancer Institute Cancer Drug Information for Aldesleukin.*               Douglas MacFarlane, Brighton (AU);        Chang, B.S. and Hershenson, S. 2002. Practical approaches to pro
               David M. Foureau, Charlotte, NC (US);       tein formulation development in “Rationale Design of stable protein
                  Iain McKillop, Charlotte, NC (US)            formulations-theory and practice” (J.F. Carpenter and M.C. Manning
                                                                           eds.) Kluwer Academic/Plenum publishers, New York. pp. 1-25.*
(73)  Assignees: The University of North Carolina at        Osmolyte effects on protein stability and solubility: a balancing act
                 Charlotte, Charlotte, NC (US); The          between backbone and side-chains. Auton M. Rösgen J. Sinev M.               Charlotte-Mecklenburg Hospital            Holthauzen LM, Bolen DW. Biophys Chem. Nov. 2011:159(1):90-9.                                                                     doi:10.1016/j.bpc.2011.05.012. Epub May 19, 2011.*                 Authority, Charlotte, NC (US); Monash                                           CDHP MW. Molecular weight of choline dihydrogen phosphate as                 University, Clayton VIC (AU)              shown on ChemSpider.*
                                                             Water MW. Molecular weight of water as shown on ChemSpider.*
(*)  Notice:    Subject to any disclaimer, the term of this    NIH Daily Med Proleukin. Molecular weight of Interleukin-2 as                 patent is extended or adjusted under 35     shown by NIH Daily Med.*
                U.S.C. 154(b) by 0 days.                     Development of a New Formulation to Enable Sustained IL-2
                                                                 Release In Vivo. David M. Foureau, Chase  P. Jones, Katherine
(21)  Appl. No.:      13/392,784                              Weaver, Regina M. Vrikkis, Douglas R. MacFarlane, Iain H. Mckil
                                                                              lop, Jonathan C. Salo, Gloria D. Elliott. Journal of Immunotherapy:
(22)  PCT Filed:     Dec. 3, 2010                                Oct. 2010—vol. 33—Issue 8  pp. 859-920. (Foureau abstract p.
                                                                      896).*
(86).  PCT No.:      PCT/US2O10/058842                    Vrikkis RM et al. Biocompatible ionic liquids: a new approach for
                                                                              stabilizing proteins in liquid formulation. Journal of Biomechanical
     S371 (c)(1),                                                 Engineering. Jul. 2009; 131: 074514-1-074514-4.        (2), (4) Date:   Apr. 5, 2012                                 Fujita Ketal. Solubility and stability of cytochrome c in hydrated
                                                                          ionic  liquids:  effect of Oxo acid  residues and  kosmotropicity.
(87)  PCT Pub. No.:  WO2011/069037                        Biomacromolecules. 2007; 8:2080-2086.
    PCT Pub. Date: Jun. 9, 2011                                 International Search Report and Written Opinion, PCT/US2010/                                                                058842, mailed Jan. 31, 2012.
(65)                Prior Publication Data                       Fujita Ketal. Choline dihydrogen phosphate. Acta Crystallographica
                                                                      Section E. 2009; E65; o709 and supplementary materials.
    US 2012/O230944 A1     Sep. 13, 2012                     Fujita Ketal. Protein solubilising and stabilising ionic liquids. The
                                                              Royal Society of Chemistry. Chem Comm. 2005; 4804-4806.             Related U.S. Application Data                                                                           Fujita K et al. Unexpected improvement in stability and utility of
(60)  Provisional application No. 61/266,197, filed on Dec.     cytochrome c by Solution in biocompatible ionic liquids. Biotechnol
       3, 2009, provisional application No. 61/286,048, filed     ogy and Bioengineering. Aug. 20, 2006: 94(6): 1209-1213.
     on  Dec.  14,  2009,  provisional  application  No.     Proleukin Pharmacology and Indications. Novartis product informa
      61/388,682,  filed  on  Oct.   1,  2010,  provisional      tion. 2009: 5 pp, retrieved Nov. 30, 2009.                                                                           Fujita et al., “Protein solubilising and stabilizing ionic liquids.”       application No. 61/412,428, filed on Nov. 11, 2010.      Chem. Commun. 4804-4806 2005.
                                                                           Fujita et al., “Enzymatic Activity and Thermal Stability of Metallo
(51)   Int. Cl.                                                        Proteins in Hydrated Ionic Liquids.” Biopolymers 93:1093-1099
    A6 IK38/20          (2006.01)                            (2010).
    A6 IK38/24          (2006.01)                         CreightonTE. Proteins: Structures and Molecular Properties, 2nd Ed.
    A 6LX39/395         (2006.01)                           Section 7.1.1 Aqueous Solubility, pp. 262-263. Section 7.4.4. Physi
    A6 IK38/02          (2006.01)                              cal Basis for Protein Denaturation, pp. 292-294. W.H. Freeman and
    A6 IK38/2I           (2006.01)                       Company. New York. 1992.
    A6 IK38/27          (2006.01)                          Constatinescu D et al. Patterns of protein unfolding and protein                                                                     aggregation in ionic liquids. Physical Chemistry Chemical Physics.    A6 IK9/00            (2006.01)                                                                            Jan. 6, 2010; 12: 1756-1763.    A6 IK38/47          (2006.01)                                                             MacFarlane DG et al. Ionic liquid “buffers'  pH control in ionic
    A6 IK 47/24          (2006.01)                             liquid systems. Chem. Commun. Sep. 27, 2010; 46: 7703-7705.
(52)  U.S. Cl.
    CPC  ........... A61 K9/0019 (2013.01); A61 K38/2013     * cited by examiner
            (2013.01); A61 K38/47 (2013.01); A61 K47/24
                                               (2013.01)    Primary Examiner — Brian J Gangle
(58)  Field of Classification Search                           Assistant Examiner — Andrea McCollum
     None                                                    (74) Attorney, Agent, or Firm — Myers Bigel & Sibley, P.A.
      See application file for complete search history.
                                                                (57)           ABSTRACT
(56)               References Cited                                                 The present invention relates to compositions and methods
              U.S. PATENT DOCUMENTS                    for the preparation, Stabilization, and/or storage of active
                                                                 agents, particularly therapeutic proteins and polypeptides
 2005/0020814 A1*   1/2005  Rudolph et al.   .............. 530/350     Such as Interleukin-2.
 2007/0093462 A1    4/2007  Rogers et al.
 2009, 0226530 A1*    9, 2009  Lassner et al.  ................ 424/497                23 Claims, 16 Drawing Sheets

---

## Page 2

U.S. Patent      Mar. 22, 2016     Sheet 1 of 16        US 9.289,381 B2

                 Figure 1
               -- TRYPAN BLUE ASSAY
              16O      "A- RESAZURN ASSAY       1O





                  O   1 O  20  30 40  50  6O  70  8O  90
               |ONIC LIQUID C CONCENTRATION (mM)
                Figure 2
     (a)            SODUMACETATE                14OOO
               k  CS 12OOO      a  FRESH
                4.    10000                - -    1 MONTH
       Q 5  8000                       - - - - 2 MONTHS
        S  6000-          IS, \       ......."  3 MONTHS
                2  Y.3  4000               S-  2000
                                    f         O                                                                                                                                                   .
                     50   60    70    80    90
                   TEMPERATURE (C)
     ( ) H    14OOO     CHOLINE-DHP
                                  res      O
      ig 6     - FRESH
                l S  6OOO                  m-- - 2 MONTHS
       O g  4000                  A      ''''''''  3 MONTHS                  2             5 st  2000
                    O  il
                     50   60    7O    8O   90
                  TEMPERATURE (C)

---

## Page 3

U.S. Patent      Mar. 22, 2016     Sheet 2 of 16        US 9.289,381 B2

          i


                   100          1 O1       102       103       104
                                FL2-H
              PHK26 malarm
                  NO C-DHP - 30 mM C-DHP


                                              30 mM C-DHP





                                                                                                      d
                                                      c
                                                                                                                  y

---

## Page 4

U.S. Patent      Mar. 22, 2016     Sheet 3 of 16        US 9.289,381 B2

                 Figure 4
        0.290 -:
                                                                                                                                           in  mmm vn 25 mg/ml HEWL IN NaOAc (a)
                           |         ----- 25 mg/ml HEWL IN NaOAC (b)
        0.240    l                                                                                      a   r                 -  25 mg/ml HEWL IN NaOAC (c)
     - 25 mg/ml HEWLIN 80% w/w CDHP (a)
            O, 190        - - - - 25 mg/ml HEWLIN 80% w/w CDHP (b)
                    :       - - - 25 mg/ml HEWLIN 80% w/w CDHP (c)
       O)                                                                                                                                                                    -       .                   .       . 25 mg/ml HEWL IN 80% w/w CDHP (d)
        0.140   w
                 11. s       0.090-:       ,  ,            WAYR                                                                                                             ...     lv.  VW                           V.,.      VAA lf                   A                                       'l'-.     .     .  V.   V.    A.V.   (N.        .                  .             .            .        0.040         v^.J.  SfSy?As  inish:

     -OOO
            3OO  350  4OO  45O  500  550  600  650  700  750
                         WAVELENGTH, nm
                 Figure 5            O. 150
                                  :  - 10 mg/ml HEWLIN NaOAC (a)
           O. 130 -                   - - - - - 10 mg/ml HEWLIN NaOAC (b)
                     irr. 10 mg/ml HEWLIN NaOAC (c)
           O. 110-  - 10 mg/ml HEWLIN 80% w/w CDHP (a)
                   - - - - 10 mg/ml HEWLIN 80% wiv CDHP (b)
        O.O90         - - - - 10 mg/ml HEWLIN 80% w/w CDHP (c)
       CO
                    ).                                                                                            ...   it
   g 0.070                                                       s
       0.050
               \a.                                                                              9
        O.O3O    WJY Raivai y YW,         2-                                               .
         O,O1 O -  &w              W        9° N,  y'?   wr y   AisY   A A. s F             As  kAssakats-Safs2 is fe-N cy Alysh Era
         -O.O1 O
           3OO  350  4OO  450  500  55O  6OO  650   7OO  750
                         WAVELENGTH, nm

---

## Page 5

U.S. Patent      Mar. 22, 2016     Sheet 4 of 16        US 9.289,381 B2

                 Figure 6         O.O3O
                                                                                                                                                                                                                          a    raad   is a  war   1 mg/ml HEWL IN NaOAC (a)
        O.O25-                    1 mg/ml HEWLIN NaOAC (b)
          or  1 mg/ml HEWL IN NaOAC (c)
     - 1 mg/ml HEWLIN 80% w/w CDHP (a)
        0.020-       --- . 1 mg/ml HEWLIN 80% w/w CDHP (b)
                  - - - 1 mg/ml HEWLIN 80% w/w CDHP (c)
        0.015
        * 0.010
          O.O.05     l'AAA'v'.?h Wy.,\ ...A Vr
                  Ai.       ifi
        O.OOO - A. i.  ft.

       -OOO5
            3OO  350  400  45O  500  55O  6OO  650  700  750
                         WAVELENGTH, nm
                Figure 7
        14OOO                                      (b)
       10500               - O MONTH
                                                                                                                                                                                                                                               a    an  w  a 1 MONTH
        7OOO                                  - - - 2 MONTH
                                           - - 3 MONTH
      Sa 3500                                                                   \     4 MONTH
    d                         N,N-  5 MONTH
            O
   g 14000
        Ol
         c  10500

        7OOO

        3500

           333     343     353     363 333     343     353     363
                    TEMPERATURE (K)

---

## Page 6

U.S. Patent      Mar. 22, 2016     Sheet 5 of 16        US 9.289,381 B2

               Figure 8
     12OOOO
                                  A 10 mg/ml CDHP
                                         E 100 mg/ml CDHP
        1 OOOOO                          A  10 mg/m NaOAC
                                         A.                                      In 100 mg/ml NaOAC
   -  80000   O
  S  g  6OOOO

  C      4OOOO

      2OOOO

           O
             O            1        2        3        4         5
                       TIME (MONTHS)
               Figure 9
     347.50                           A 10 mg/ml CDHP
                                                                                     in  100 mg/ml CDHP
                                    A 10 mg/ml NaOAC
     347. OO                             o 100 mg/ml NaOAC
                                                                                                                  f
              3334.4.566  5O5 OOO                i      i     345.00

     344,50
            O              1         2        3        4        5
                        TIME (MONTHS)

---

## Page 7

U.S. Patent      Mar. 22, 2016     Sheet 6 of 16        US 9.289,381 B2

                Figure 10
           25
                                       A 10 mg/ml CDHP
                                                                      E  100 mg/ml CDHP
          2O                          A  10 mg/m. NaOAC
         CS                                O  100 mg/ml NaOAC    S
           15

      >   10         u
    O
         C
            5

            O
              O             1        2        3               4.        5
                         TIME (MONTHS)
                Figure 11
         30                          -A-10 mg/ml CDHP
                        -- 100 mg/ml CDHP
         2O                         -a - 10 mg/ml NaOAC
                                      -8- 100 mg/ml NaOAC


          10




                        TIME (MONTHS)

---

## Page 8

U.S. Patent      Mar. 22, 2016     Sheet 7 of 16        US 9.289,381 B2


                 Figure 12





                 Figure 13
       65OOO       O% WIW CDHP
                  5% WIW CDHP
                   10% WIW CDHP
       55OOO       20% WIW CDHP
                  30% WW CDHP
                 40% w/W CDHP
       45000       20% w/w CHOLINE
                     CHLORIDE
    &        3 5 O O O                                                               s  --               ".
                Dolorado       A AAAAAA.
       25OOO





            340     345     350     355     365     365    370
                       TEMPERATURE (K)

---

## Page 9

U.S. Patent      Mar. 22, 2016     Sheet 8 of 16        US 9.289,381 B2

                 Figure 14
          362
          360
       2 358
          356
          354
          352
          350
          348
          346
               O     5    1O    15   20   25   30   35   40
                % Whw CDHP NO.1 M NaOAC
                 Figure 15
       16OOOO
       14OOOO
       12OOOO
     o 100000
        8OOOO
        6OOOO
        4OOOO
        2OOOO
             O
              O    5    1O    15   20   25   30   35   40
                 % WIW CDHP N 0.1 M NaOAC

---

## Page 10

U.S. Patent      Mar. 22, 2016     Sheet 9 of 16        US 9.289,381 B2

                 Figure 16
          450
          4OO
          350
         S2 300
      £250
     3200
          150     2
          1OO
           5O

              O    5    10    15   20   25   30   35   40
                % WFW CDHP N 0,1 MNaOAC
                Figure 17
        3OOOO

        25OOO

        2OOOO

        15OOO

             1 OOOO

         5OOO


              O     5    10    15   20   25   30   35   40
                 % WIW CDHR NO.1 MNaOAC

---

## Page 11

U.S. Patent      Mar. 22, 2016     Sheet 10 of 16       US 9.289,381 B2

                Figure 18
    (a)         h         (d)       Q
            H-1 -o  ro- o-Cu
                                O


               O                  O
           p                s    (C) N1-a-O-F5               -R-O                           //          -V  \
             O                        S



                14

                         1.2

                        1.O                    D REHALOSE
                                         v NaC
                 f  O.8                  A CHOLINE CHLORIDE
                                                                                                                                  a CDBP
                       0.6                     e CDEP
                      s
                 >  0.4
                  O.2-

                       O.O

                       -0.2
                         O   1  2  3  4  5
                    LOG CONCluM

---

## Page 12

U.S. Patent      Mar. 22, 2016     Sheet 11 of 16       US 9.289,381 B2

               Figure 20
                       1.4

                12
                       1.O             X CTMP

                      O.8

                      0.6

                     O.4

                     O.2

                     O.O

                      -0.2
                      O    1  2  3  4  5
                  LOG CONC/uM
               Figure 21





                       O   1  2  3  4  5
                  LOG CONC/uM

---

## Page 13

U.S. Patent      Mar. 22, 2016     Sheet 12 of 16       US 9.289,381 B2

               Figure 22
      (a)
                  5

             s           a  4
                d5  3                  A CHOLINE CHORIDE
                               CDHP
         C  2                  CDBP
           -                         % CBEH
                                             x CTMP
                            1                       9 CDEP
                                   AD.J. R-SCUARE - O.83   v SODUM CHLORIDE

             O W - ON  (Y) w    () (ON  OO. O. O. vo
                          CD CO CO. O.     O. O. C.    O. C. O - Y  -
      (b)        OSMOTC COEF.


                                 A CHOLINE CHORIDE
              40                 CDHP
            2 35                        x CMP
              30                        e CDEP
              25                 D 20
        C 15
                        1 O


                     A), R-SQUARE = 0.98

                         O. O.  O.2  0.4  O. 6  O.8  1.O
            ANON MASS FRACTION

---

## Page 14

U.S. Patent      Mar. 22, 2016     Sheet 13 of 16       US 9.289,381 B2


                  Figure 23





           O     100   200   300   400   500   600   700   800
                        TEMPERATURE7°C

                 Figure 24
      (a)                    (b)
        2       SPLENOCYTES               B16-F1 O CELS
            as 189                          9 is  39                         9           16                            6      S   149                st 149
      Y 1291gglé-AA-AA-AA-s-s-s-s-s-   pH8       - 12019      E 89.                                 St.  89
     2g5e  5.                      a     7 2g2Q  5.8     s 3 O    20   40   60it,80  it isO    20   40   60-80
          C-5HP conCENTRATION (i) A   C-5HP CóNCENTRATION (mM)
                  TRYPANBLUE         RESAZURN
                  EXCLUSION TEST      REDUCTIONASSAY
                        pH MEASUREMENTS

---

## Page 15

U.S. Patent      Mar. 22, 2016     Sheet 14 of 16       US 9.289,381 B2

                 Figure 25
                   O
                                  -o- 10% FBS                  9                                  -v- 5% FBS
             pH 8                    -o- 1% FBS
                  7                    -o- O, 1% FBS
                      6                                              A  15% SODUM
                   5                       BCARBONATE
                      O  1 O2O3O4O 506O7O 8O
     (b)     C-DHP CONCENTRATION (mm)     F-1a   SPENOCYTES    9 it.   B16-F1 O CELLS     9
  s352 geS-Sc.--
    92 f                    P2 is
        c5-p dencerRaion o   cip (SCERRAN o
      -- EXESE-Est -a-. RE6  Ssay
                            pH MEASUREMENTS
     (a)           Fiduregure 262)     e                                     1OO
    gal                                80
     52.                 s 60                                                                                                      -
          2,  38                    940
    is 2.                              20       "as gisa is   is            CONCENTRATION (mM)            100    101
       -      RESAZURN         PHK26 ama-a--
            REDUCONASSAY                                :::::::: NO C-DHP
  % pH MEASUREMENTS    s 30 mM C-DHP

---

## Page 16

U.S. Patent      Mar. 22, 2016     Sheet 15 of 16       US 9.289,381 B2

                  Figure 27
      (a)                    (b)        CRCULAR DICHROSM
        THERMAL PROFE. F.                   1 OO
          SGMODA. C. RWES
         NTEREUKEN-2 STABZNG
          EXCPENT TRAL                80
        20% (w) CDHP pH 740 T-45.5c          30 mM CDHP, pH 7.40, T=52.3 C   S 60
          30 mM NaHPO, pH 7.40, T=53.9 C
                           O 40
           15 TO 75 C, 30 C/HOUR           S
     - 20% CDHP (-1 M CDHP)           20
           -- 30 mM CDHP (-0.5% CDHP)
                                                                     a 30 mM NaHPO,                    O                                                     100
                1.0
     OG    0.8                     PHK26 mala--
              l
    20.6                                                                                                  : NO C-DHP      DN     2 cy                                     30 mM C-DHP
          9.               0.2
          C
               0.0
                1O 20 30 40 50 60 70 80
               TEMP (C)
      (C)       NO C-DHP                  30 nM C-DHP
                1 OOO          -  -     ---

          8O

         I. 600     O
              CfO
         CO 400





                                                O  o
                                                                     we

---

## Page 17

U.S. Patent      Mar. 22, 2016     Sheet 16 of 16       US 9.289,381 B2


     (a)  5000      Figure 28

                O  f's     -- MEAN RESIDUE ELLIPTICITY

            -5000

                    - 1 OOOO

                  - 15000

           -2OOOO

           -25000
                190      2OO     210      22O      230     240
                       WAVELENGTH (nM)
     (b)
     - 30 mM NaHPO,
                       - -  - 30 mM CDHP
                0.8                 '   '  '  '  185 mM CDHP
                       "  " -  680 nM. CDHP

                O.6


               0.4


                0.2


               O.O
                  2O    30   40    50    6O    70    8O    90
                         TEMPERATURE (C)

---

## Page 18

US 9,289,381 B2
                                              1.                                         2
      STABILIZATION AND STORAGE OF            and handling of these therapeutics in liquid formulations.
      BOLOGICAL PHARMACEUTICAL              Factors such as pH, temperature, ionic strength, physical
            COMPOSITIONS                           agitations, and cycles of freeze-thaw often result in the desta
                                                                     bilization and loss of biological activity of the proteins. Lyo
        RELATED APPLICATION DATA                  philization provides the protein in a dried form and involves
                                                               freezing the protein at atmospheric pressure, removing the
  This application is a 35 U.S.C. S371 national phase entry of    water in a low pressure chamber, and collecting the Sublimed
PCT Application PCT/US2010/058842, filed Dec. 3, 2010,     frozen  water on  a  condenser.  However,  lyophilization
and published in English on Jun. 9, 2011, as International     requires more handling, increased processing time, a non
Publication No. WO 2011/069037, and which claims the  10  reactive and completely air-tight storage container, a sterile
benefit of U.S. Provisional  Patent Application  Ser. No.     Solvent during reconstitution, possibly a separate container
61/266,197, filed Dec. 3, 2009, U.S. Provisional Patent Appli     for the sterile reconstitution solvent, and complex equipment
cation Ser. No. 61/286,048, filed Dec. 14, 2009, U.S. Provi     including a drying chamber, condenser, vacuum pump,sional Patent Application Ser. No. 61/388,682, filed Oct. 1,                                                                       15  refrigeration system, and controller devices. It also must be2010, and U.S. Provisional  Patent Application  Ser. No.                                                                 reconstituted prior to injection, which requires a trained indi61/412,428, filed Nov. 11, 2010, the disclosures of all of                                                               vidual and time for the protein to go into solution completely.which are incorporated herein by reference in their entirety.                                                              All of these factors increase the cost of manufacture and
    STATEMENT OF GOVERNMENT SUPPORT             difficulty of parentaral administration of protein therapeutics
                                                                      in the powdered form.
  This invention was made with government Support under       Liquid formulation can eliminate the long, expensive lyo                                                                   philization process in favor of a product that is much simpleraward number SBE0548401 by the National Science Foun
dation and award number 1R21EB00740401A2 by the     for the end user to employ. Liquid formulations can be
National Institutes of Health. The United States government    cheaper to manufacture and preferred by physicians. Unfor
has certain rights to this invention.                             25  tunately, any water molecules present tend to foster degrada
                                                                   tion of proteins. If the tendency towards protein degradation
           FIELD OF THE INVENTION                     in liquid formulation can be overcome, the cost of protein
                                                                 therapeutics can be substantially reduced.
  The present invention relates to compositions and methods       Accordingly, there is a need in the industry for novel for
for the preparation, stabilization, and/or storage of polypep  30 mulations and compositions containing therapeutic proteinstides, particularly therapeutic polypeptides.                                                     which promote the stability and maintain the biological activ
     BACKGROUND OF THE INVENTION                 ity of the proteins before administration to a patient.                                                   The present invention addresses previous shortcomings in
                                                              the art by providing compositions and methods for the prepa  The use of biological therapeutics to treat a range of medi  35                                                                       ration, stabilization, and/or storage of polypeptides, particucal conditions is becoming increasingly popular in modern                                                                        larly therapeutic polypeptides.medicine. These pharmaceutical compositions may contain
an active ingredient such as a protein and a pharmaceutically
acceptable carrier or solvent. Proteins are biological mol         SUMMARY OF THE INVENTION
ecules that elicit a specific response in the human body, thus 40
the pharmaceutical industry has an interest in using these    A  first aspect of the present invention is a parenterally                                                                   injectable pharmaceutical composition comprising, consistbiomolecules as drugs to cure and manage disease. Protein
drugs tend to be unstable as a result of their complex three     ing of or consisting essentially of
dimensional structures. The interaction within, and the com        (a) from 0.01 to 50 weight percent choline dihydrogen
plexity of this structure means more components can be bro  45 phosphate (CDHP):
ken down or denatured, and as protein function depends on        (b) from 0 to 50 weight percent of a base (e.g., choline
this structure integrity, protein drugs are difficult to store and     hydroxide, Sodium hydroxide, etc.);
maintain. The formulation of protein based drugs present the        (c) at least 50 weight percent water;
challenge of keeping the protein folded during isolation,        (d) from 0.01 to 10 weight percent active compound (e.g. a
                                                                50  protein or polypeptide active compound) selected from themanufacture, and patient use.
   Protein drugs, which can be quickly digested and left use    group consisting of Interleukin-2, gelsolin, antibodies (e.g.
less if taken orally, generally must be given by injection.    monoclonal antibodies such as humanized monoclonal anti
Proteins are very unstable in the gastrointestinal tract, being     bodies and including non-glycosylated antibodies); erythro
hydrolyzed and broken down by its acids and enzymes. The     poietin, interferon, human growth hormone, folicle stimulat
                                                                  55  ing hormone, and granulocyte colony Stimulating factor; andoral bioavailability can be as low as <1% due to the effect that
their large size and hydrophillicity has on membrane perme        (e) from 0, 0.01 or 0.1 to 30, 40 or 50 weight percent of at
ability (MacNally & Park, 1990; Lee, Dodda-Kashi, Grass, &      least one compatible osmolyte.
Rubas, 1990). Parenteral administration, which has 100%        In some embodiments of the foregoing, the composition
bioavailability, is usually the preferred method for delivering     preferably has a pH of from 6 or 6.5 up to 7.5 or 8.
protein therapeutics.                                            60    In some embodiments of the foregoing, the water is
  Also, minimization of manufacturing costs while main     included in an amount of at least 60, 70 or 80 weight percent
taining protein integrity is of paramount importance. Proteins    up to 95 or 99 percent.
in pharmaceutical compositions are typically packaged and       In some embodiments of the foregoing, the base is included
stored in a lyophilized State to maintain their biological activ     in an amount of not more than 20, 30 or 40 weight percent.
ity. Inherent physical instabilities of the polypeptides includ  65    In some embodiments of the foregoing, the choline dihy
ing denaturing, deamination, and the formation of soluble and    drogen phosphate is included in an amount of not more than
insoluble aggregates have become a problem for the storage     20, 30 or 40 weight percent.

---

## Page 19

US 9,289,381 B2
                   3                                        4
   In some embodiments of the foregoing, the base and the    0.1M NaOAc, (C) 100 mg/ml and stored in 80% w/w CDHP.
choline dihydrogen phosphate are included togetherina com     (D) 100 mg/ml and stored in 0.1M NaOAc at 0, 1, 2, 3, 4, and
bined amount not more than 20, 30, 40 or 50 weight percent.     5 months.
   In some embodiments of the foregoing, the composition is       FIG.8. Enthalpy change of unfolding of HEWL stored at
a single phase solution.                                    10 and 100 mg/ml in 80% w/w CDHP or 0.1M NaOAc.
   In some embodiments of the foregoing, the composition       FIG.9. Thermal transition midpoint temperature of HEWL
has an osmolality of 100 to 700 milliOSmoles or 3,000 mil     stored at 10 and 100 mg/ml in 80% w/w CDHP or 0.1M
liOSmoles.                                        NaOAC.
   In some embodiments of the foregoing, the active agent is       FIG. 10. Enzyme activity of HEWL formulated at 10 and
Interleukin-2, such as human Interleukin-2 and particularly  10  100 mg/ml in 80% w/w CDHP or 0.1M NaOAc.
aldesleukin; in other embodiments, the active agent is gelso       FIG.  11. Average percent difference of measured  vs.
lin Such as human gelsolin.                               assumed aliquot protein concentration over time.
   In some embodiments of the foregoing, the active agent is       FIG. 12. Contamination vials from left to right: positive
recombinant (e.g., a recombinant protein or peptide) and/or is     control, negative control, sample CDHP formulation, sample
non-glycosylated.                                                   15 NaOAc formulation.
 A further aspect of the invention  is a composition as       FIG. 13. DSC scans of HEWL formulated at 1 mg/ml in 0,
described herein packaged in a sterile container.                   5, 10, 20, 30, and 40% w/w CDHP in 0.1M NaOAc or 20%
 A further aspect of the invention is a method of treating a    w/w choline chloride in 0.1M NaOAc.
disorder in a subject in need thereof, comprising administer       FIG.  14. Thermal  transition midpoint temperature of
ing said Subject a treatment effective amount of a composition   HEWL formulated at 1 mg/ml in 0, 5, 10, 20, 30, and 40%
as described herein.                           CDHP in 0.1M NaOAc.
 A further aspect of the invention  is a composition as       FIG. 15. Enthalpy change of unfolding of HEWL formu
described herein for use in treating a disorder in a Subject in     lated at 1 mg/ml in 0, 5, 10, 20, 30, and 40% w/w CDHP in
need thereof.                                     O.1MNaOAC.
  The foregoing and other aspects of the present invention  25    FIG. 16. Entropy change of unfolding of HEWL formu
will now be described in more detail with respect to other     lated at 1 mg/ml in 0, 5, 10, 20, 30, and 40% CDHP in 0.1M
embodiments described herein. It should be appreciated that    NaOAC.
the invention can be embodied in different forms and should       FIG. 17. Gibbs free energy of unfolding at room tempera
not be construed as limited to the embodiments set forth     ture for HEWL (1 mg/ml) solutions in increasing amounts of
herein. Rather, these embodiments are provided so that this  30 CDHP.
disclosure will be thorough and complete, and will fully       FIG. 18. Structures and names of compounds examined.
convey the scope of the invention to those skilled in the art.       (a) choline, (b) dihydrogen phosphate, (c) dibutyl phosphate,                                                                    (d) bis(2-ethylhexyl)phosphate, (e) bis(2,4,4-trimethylpen
     BRIEF DESCRIPTION OF THE DRAWINGS           tyl)phosphinate, (f) O,O'-diethyl dithiophosphate.
                                                                  35    FIG. 19. Dose response curves for J774 indicating toxicity
  FIG.  1. FIG. 1 shows that freshly isolated splenocytes     effect of ionic liquids. Raw data and fitted concentration
remain viable when exposed to 30 mM or less CDHP 5x10     curves (dose response model, Equation 1) are shown.
splenocytes were incubated 24 hours in complete medium       FIG. 20. Dose response curves for J774 indicating toxicity
containing increasing concentrations of CDHP. Cell viability     effect of ionic liquid choline bis(2,4,4-trimethylpentyl) phos
was then measured by trypan blue (Squares) or resaZurin 40 phate (CTMP). Raw data and fitted concentration curves
assays (triangle) and normalized with control splenocytes     (dose response model, Equation 1).
viability (CDHP viability/no CDHP viability*100). N=15       FIG. 21. Dose response curves for J774 indicating 3ollicle
from 5 independent experiments.                                    effects. Raw data and fitted concentration curves (modified
  FIG. 2. FIG. 2 illustrates CDHP increases lysozyme stabil     logistic model, Equation 2) for choline bis(2-ethylhexyl
ity. Thermal analysis was performed on 100 mg/ml lysozyme 45 phosphate (CBEH) and CDHP.
formulations, containing sodium acetate (FIG. 2a) or CDHP      FIG.22. Effect of osmotic coefficient and anion mass frac
(FIG.2b), stored at room temperature for one to three months.     tion on viability. (a) The osmotic coefficient of each anion is
  FIG.  3. CDHP does  not impact  interleukin-2  (IL-2)     plotted against the Log ECs. Adj. R-square=0.83. (b) The
thermo-stability but increases  IL-2-dependant HT-2  cell     anion mass fraction versus ECso mM. The mass fraction (X)
                                                                50 of each anion is expressed as in the equation (X m/m), whereviability under buffered conditions in vitro. A and B. HT-2
cells were stained with PKH26 and incubated with IL-2     the mass of each component i is defined as its amount m,
(100U) in complete RPMI 1640 buffered medium containing     divided by the total amount of substance in the system, m.
0 or 30 mM CDHP. At T+72 h, cell proliferation was quanti     Adj. R-square=0.98. Data analyzed with OriginPro8, error of
fied by flow cytometry and cell viability measured based on      last digit in parenthesis.
morphological criteria. CDHP did not significantly affect  55    FIG. 23. Thermogravimetric Analysis (PerkinElmer) of
IL-2-induced HT-2 lymphocyte proliferation under buffered     choline ILs. Scan rate was 10.0°C/min from room tempera
conditions but significantly improved cell viability. n=9 from     ture to 800° C. under a nitrogen atmosphere.
3 independent experiments.                                   FIG. 24. C-DHP cytotoxic concentration (40 mM) corre
  FIG. 4. Absorbance at various wavelengths in 25 mg/ml      lates with pH changes. Freshly isolated spleen leucocytes or
                                                                  60 B16-F10 cells, were cultured in RMPI 1640 or DMEM F12hen egg white lysozyme (HEWL) formulated in 80% w/w
CDHP or 0.1M sodium acetate (NaOAc).                     complete medium respectively, supplemented with up to 80
  FIG. 5. Absorbance at various wavelengths in 10 mg/ml   mMC-DHP. At T0, culture medium pH was measured and at
HEWL formulated in 80% W/w CDHP or 0.1M NaOAc.       T+24" cell viability was measured by trypan blue exclusion
  FIG. 6. Absorbance at various wavelengths in  1 mg/ml     (black line) or resaZurin reduction assay (grey line). A) Up to
HEWL formulated in 80% W/w CDHP or 0.1M NaOAc.      65 40 mM, C-DHP has no significant cytotoxicity toward pri
  FIG. 7. DSC scans of HEWL formulated at (A) 10 mg/ml    mary cell cultures of splenocytes. However, at >40 mM
and stored in 80% w/w CDHP (B) 10 mg/ml and stored in    C-DHP, culture medium pH is <6.5 and cell viability dimin

---

## Page 20

US 9,289,381 B2
                   5                                           6
ishes. B) Despite a dramatic reduction of pH, C-DHP doesn’t      The terminology used in the description of the invention
demonstrate any significant cytotoxic activity against B16     herein is for the purpose of describing particular embodi
F10 cells, n=18 from 6 independent experiments (right chart,    ments only and is not intended to be limiting of the invention.
grey line resaZurin reduction assay, black line trypan blue    As used in the description of the invention and the appended
exclusion).                                                     claims, the singular farms “a”, “an and “the are intended to
  FIG. 25. C-DHP biocompatibility in vitro increases under     include the plural forms as well, unless the context clearly
buffered conditions. A) Effect of fetal bovine serum (FBS)     indicates otherwise.
content or sodium bicarbonate addition on complete RPMI       Unless otherwise defined, all terms (including technical
1640 medium pH was measured. While FBS content had no    and Scientific terms) used herein have the same meaning as
significant effect on C-DHP culture medium acidification,  10 commonly understood by one of ordinary skill in the art to
1.5% (w/v) sodium bicarbonate maintained pH within physi    which this invention belongs. It will be further understood
ological range. B) Freshly isolated mouse spleen leucocytes     that terms, such as those defined in commonly used dictio
or B16-F10 cells were cultured in buffered (1.5% (w/v)     naries, should be interpreted as having a meaning that is
sodium bicarbonate) RMPI 1640 or DMEM F12 complete     consistent with their meaning in the context of the present
medium supplemented with sk0 mMC-DHP. At T0, culture  15  application and relevantart and should not be interpreted in an
media pH was measured and at T+24" cell viability was     idealized or overly formal sense unless expressly so defined
measured using trypan blue exclusion (black line) or resa     herein. The terminology used in the description of the inven
Zurin reduction assays (grey line). Under buffered culture     tion herein is for the purpose of describing particular embodi
medium  conditions, no  cytotoxic  activity was  detected    ments only and is not intended to be limiting of the invention.
toward either cell type within a 0-80mMC-DHP range. N=15     All publications, patent applications, patents and other refer
from 6 independent experiments.                             ences mentioned herein are incorporated by reference in their
  FIG. 26. C-DHP inhibits IL-2 activity in vitro in the      entirety.
absence of pH control. A) HT-2 cells were grown in complete      Also as used herein, “and/or  refers to and encompasses
RPMI 1640 medium supplemented with 100 UIL-2 and s40    any and all possible combinations of one or more of the
                                                                  25  associated listed items, as well as the lack of combinationsmMC-DHP. Cell viability at T+24" was measured by resa
Zurin reduction assay. B) HT-2 cells were stained with PKH26    when interpreted in the alternative (“or).
and incubated with 100 U IL-2 in complete RPMI 1640       Unless the context indicates otherwise, it is specifically
medium containing 0 or 30 mMC-DHP. At T+24", cell pro     intended that the various features of the invention described
liferation was quantified by flow cytometry. While C-DHP     herein can be used in any combination.
has no immediate cytotoxic effect toward HT-2 lymphocytes,  30    Moreover, the present invention also contemplates that in
a low concentration of the ionic liquid dramatically reduced    Some embodiments of the invention, any feature or combina
IL-2 induced cell proliferation in vitro. N=9 from 3 indepen     tion of features set forth hereincan be excluded or omitted. To
dent experiments.                                                        illustrate, if the specification states that a complex comprises
  FIG. 27. C-DHP does not impact IL-2 thermo-stability but    components A, B and C, it is specifically intended that any of
increases IL-2-dependent HT-2 cell viability under buffered  35 A, B or C, or a combination thereof, can be omitted and
conditions in vitro. A) IL-2 thermal stability was measured     disclaimed.
between 15-75° C. by circular dichroism at 222 nm. In the     As used herein, the transitional phrase "consisting essen
presence of 30 mMC-DHP, the melting point of IL-2 was not      tially of  (and grammatical variants) is to be interpreted as
modified. B) and C) HT-2 cells were stained with PKH26 and    encompassing the recited materials or steps and those that do
incubated with IL-2 (100U) in complete RPMI 1640 buffered 40 not materially affect the basic and novel characteristic(s) of
medium containing 0 or 30 mMC-DHP. At T+72", cell pro     the claimed invention. See, Inre Herz, 537 F.2d 549, 551-52,
liferation was quantified by flow cytometry and cell viability    190 U.S.P.Q. 461, 463 (CCPA 1976) (emphasis in the origi
measured based on morphological criteria. C-DHP did not      nal); see also MPEPS2111.03. Thus, the term “consisting
significantly affect IL-2-induced HT-2 lymphocyte prolifera     essentially of  as used herein should not be interpreted as
tion under buffered conditions but significantly improved cell  45  equivalent to "comprising.”
viability. n=9 from 3 independent experiments.                The term “about,  as used herein when referring to a mea
  FIG. 28. (A) Representative Dichroweb circular dichroism     Surable value Such as an amount or concentration (e.g., the
spectral output. IL-2 in 680 mMCDHP. pH 7.40. Experimen    weight percent of the active compound in the composition)
tal (input) data plotted with crosses, the calculated spectrum    and the like, is meant to encompass variations of 20%, 10%,
derived from the calculated output secondary structure plot  50 5%, 1%, 0.5%, or even 0.1% of the specified amount.
ted with open boxes. (B) Circular dichroism temperature        In describing the invention, it will be understood that a
denaturation curves for IL-2 in (straight) 30 mM NaH2PO,    number of techniques and steps are disclosed. Each of these
(dash) 30 mM CDHP (dot) 185 mM CDHP, and (dash-dot)    has individual benefit and each can also be used in conjunc
680 mMCDHP, all at pH 7.40. The CD signal was monitored     tion with one or more, or in some cases all, of the other
                                                                  55at 222 nm, adjusted by the mean-residue-weight, and normal     disclosed techniques. Accordingly, for the sake of clarity, this
ized so that the lowest and highest signal in each scan was set     description will refrain from repeating every possible combi
to 0 and 1 respectively.                                         nation of the individual steps in an unnecessary fashion. Nev
                                                                      ertheless, the specification and claims should be read with the
   DETAILED DESCRIPTION OF THE INVENTION        understanding that Such combinations are entirely within the
                                                                  60 Scope of the invention and the claims.
  The present invention will now be described more fully
hereinafter. This invention may, however, be embodied in                                          I. Definitions
different forms and should not be construed as limited to the
embodiments set forth herein. Rather, these embodiments are       “Polypeptide.” “protein,  and "peptide' as used herein
provided so that this disclosure will be thorough and com  65  refer to a chain of covalently linked amino acids. Unless
plete, and willfully convey the scope of the invention to those     otherwise indicated, the term “polypeptide' encompasses
skilled in the art.                                           both peptides and proteins. In general, the term "peptide' can

---

## Page 21

US 9,289,381 B2
                  7                                         8
refer to shorter chains of amino acids (e.g., 2-50 amino acids);     formate, lactate, acetate, propanoate and benzoate and Sul
however, all three terms overlap with respect to the length of    phonates, such as mesylate, triflate, tosylate, and besylate.
the amino acid chain. Polypeptides may comprise naturally    Organic salts suitable for use according to certain non-limit
occurring amino acids, non-naturally occurring amino acids,     ing embodiments may include, but are not limited to, ethy
or a combination of both. The polypeptides may be isolated  5  lammonium nitrate (hereinafter referred to as “BAN), dim
from Sources (e.g., cells or tissues) in which they naturally    ethylammonium    hydrogen     sulfate   (DMAHSO4),
occur, produced recombinantly in cells in Vivo or in vitro or in    dimethylammonium  triflate  (TEATf),  triethylammonium
a test tube in vitro, or synthesized chemically. Such tech    methane sulfonate (TEAMs), choline dihydrogen phosphate
niques are known to those skilled in the art. See, e.g., Sam    (CDHP), and related compounds.
brook et al., Molecular Cloning: A Laboratory Manual 2nd  10    “Ionic liquid” as used herein refers to a substance com
Ed. (Cold Spring Harbor, N.Y., 1989); Ausubel et al. Current    posed only of ions that remains in the liquid state below the
Protocols in Molecular Biology (Green Publishing Associ     boiling point of water and more preferably at room tempera
ates, Inc. and John Wiley & Sons, Inc., New York). Accord      ture. Ionic liquids are low melting point (typically less than
ingly, “polypeptide.” “protein, and "peptide' as used herein    about 100° C.) compounds made of a cation and an anion.
encompass all naturally occurring, synthetic, and recombi  15 These non-aqueous polar solvents have a very low vapor
nant polypeptides and biologically active variants thereof.       pressure, can Solvate a wide variety of compounds, and are
  “Therapeutic protein', “therapeutically active polypep     thermally,  electrically, and chemically  stable. They are
tide.” “therapeutic polypeptide.” and “therapeutic peptide'     organic salts, as defined herein, which are larger and more
(and grammatical variations thereof) as used herein refer to    complex than common salts, such as sodium chloride. A
polypeptides, proteins, peptides, or biologically active vari     delocalization of charge on the anion limits their ability to
ants thereof which bring about a desired therapeutic response    form a crystal lattice easily, resulting in a low melting point.
in a patient Such as, for example, the prevention, treatment, or    At room temperature, their ions are organized in a less com
diagnosis of a disease or medical condition.                    pact manner and are free to interact with any solutes present.
  By the term “treat,” “treating or “treatment of (and gram     Ionic liquids can thus replace water and other solvents in a
                                                                  25matical variations thereof) it is meant that the severity of the     range of applications, such as, but not limited to protein-based
Subjects condition is reduced, at least partially improved or     pharmaceutical formulations intended for parenteral injec
ameliorated and/or that some  alleviation,  mitigation  or     tion.
decrease in at least one clinical symptom is achieved and/or      The anion and cation choice of the ionic liquid can be
there is a delay in the progression of the disease, disorder, or     tailored to provide desired solvent characteristics. Such as
medical condition.                                            30  polarity, Viscosity, hydrogen bonding capacity, miscibility,
 A “treatment effective” amountas used herein is an amount    and conductivity. Ionic liquid properties (polarity, miscibility,
that is sufficient to treat (as defined herein) the subject, Those     hydrophobicity, etc.) can be tailored by varying the properties
skilled in the art will appreciate that the therapeutic effects     of the cation and anion, such as, but not limited to, varying the
need not be complete or curative, as long as some benefit is     side chain length of the cation and the type of anion (Fujita,
provided to the subject.                                         35 MacFarlane, & Forsyth, 2005) (Fujita, Forsyth, MacFarlane,
  "Acid' as used herein refers to various water-soluble com     Reid, & Elliott, 2006). In some embodiments of the present
pounds with a pH less than 7 that can be reacted with a base     invention, the ionic liquid can be tailored to interfere posi
to form a salt. Exemplary acids can be monoprotic or polypro     tively with hydrogen bonding as well as electrostatic and
tic and can comprise one, two, three, or multiple acid func    hydrophobic interactions that govern the protein function.
tional groups.                                                40    Non-limiting examples of ionic liquids which are included
  "Organic acid' as used herein refers to an organic com     as aspects of the present invention include ethylammonium
pound that is an acid, as defined herein. Exemplary organic      nitrate (hereinafter referred to as “EAN), dimethylammo
acids include, but are not limited to carboxylic acids, Sulfonic    nium hydrogen sulfate (DMAHSO4), dimethylammonium
acids, alkanoic acids, and halogenoalkanoic acids. Organic      triflate  (TEATf),  triethylammonium  methane  sulfonate
acids  Suitable for use according to  certain non-limiting 45 (TEAMs), and related compounds.
embodiments may include, but are not limited to, lactic acid,       “Hydrated ionic liquid” as used herein refers to a mixture
citric acid, formic acid, acetic acid, propionic acid, butanoic     of water and an organic salt, as defined herein, that is liquid at
acid, uric acid, ascorbic acid, triflic acid, oxalic acid, malic    room temperature.
acid, Succinic acid, fumaric acid, ascorbic acid, tartaric acid,
                                                                50                                 II. Compositionsglucono delta-lactone, and combinations thereof.
  “Base' as used herein refers to a compound with a pH more
than 7 that can be reacted with an acid to form a salt. Exem      The present invention describes compositions and methods
plary bases include, but are not limited to: (i) oxides, such as     relating to the preparation, stabilization, and/or storage of
metal oxides, (ii) hydroxides, such as organic and inorganic     polypeptides. Such as, but not limited to, therapeutic polypep
(e.g., metal) hydroxides, (iii) amines or amine functionalized 55  tides. In certain embodiments of the present invention, the
molecules, (iv) salts of organic acids (eg metal salts of car     composition provides  for the preservation and Sustained
boxylic acids), (v) amino acids, etc.                                activity of therapeutic polypeptides. In particular embodi
  “Compatible osmolyte' as used herein refers to a com     ments, the composition is Suitable for parenteral injection.
pound Such as an amino acid (including derivatives thereof),        In some embodiments of the present invention, the com
polyols, and methylamines. Particular examples include, but  60  position comprises, consists of, or consists essentially of an
are not limited to, sarcosine, betaine, glycine-betaine, myo     organic salt (which may or may not be liquid at room tem
inositol, glycine, proline, glycerol, glucose, dissacharides     perature) and water. In other embodiments of the present
Such as trehalose, mannitol, etc. A compatible osmolyte may     invention, the composition comprises, consists of, or consists
be used individually or in combination with others               essentially of an organic acid, an organic salt (which may or
  "Organic salt  as used herein refers to an ionic compound  65 may not be liquid at room temperature), and water. Preferably
that is a salt and comprises an organic ion. Exemplary organic     the organic acid and organic salt are a conjugate acid base
salts include, but are not limited to, carboxylates, such as      pair, but this need not necessarily be the case. Any Suitable

---

## Page 22

US 9,289,381 B2
                   9                                        10
biocompatible acid and salt can be mixed to form the medium      High density water, HDW, describes the organization of
of utility in this invention. Mixing of the organic acid and    water molecules when they  interact more strongly with
organic salt can provide the optimal proton activity in the     another hydrophilic molecule than with each other. Water
medium for the purposes of stabilization of the dissolved    molecules arrange themselves in Such a way as to maximize
protein. Each protein has a different response to proton activ  5  the amount of interaction with the hydrophilic substance,
ity (related to its isoelectric point). In certain embodiments of     leading to weaker, bent or broken hydrogen bonding between
the present invention, the composition provides an adjustable    each other. HDW  is encouraged by the presence of ionic                                                           kosmotropes. Compounds labeled as ionic kosmotropes aremedium that can be tuned to the optimum proton activity for                                                                  Small, multiple charged ions with a high charge density thateach protein by varying the acid/salt ratio. In other embodi                                                                    10  interact very strongly with water molecules. Kosmotropes arements, the pH of the composition can be adjusted to reduce                                                                   typically anions, because anions are more strongly hydratedpain and injury at the injection site for parenteral injections of                                                            than similarly charged, bulkier, larger cations. It is generallythe composition.                                                            accepted that kosmotropes stabilize proteins by organizing  The compositions of the present invention can comprise an                                                         water molecules a preferential manner.
organic salt and/or an organic acid in an amount of about 0 to  15   By comparison, ionic chaotropes do not interfere withabout 50 weight percent of the composition. In particular                                                       hydrogen bonding between water molecules, because they
embodiments of the present invention the organic salt is cho     are large, singly charged, and have a low charge density. Theirline dihydrogen phosphate.                                                weak interaction with water encourages the formation of
   In Some aspects of the invention a base can be present in an   LDW. The ionic chaotrope is free to interact with the protein,
amount of about 0 to about 50 weight percent of the compo    whether positively or negatively.  It has been shown that a
sition. In particular embodiments of the present invention the    combination of kosmotropic anions and chaotropic cations
base is choline hydroxide.                                   tend to stabilize proteins, so a stabilizing medium should have
  The composition can comprise water in an amount of about    a balance of the two.
7 percent to about 100 percent, about 20 percent to about 100      Choice of ionic liquid should be made with consideration
percent, or about 50 percent to about 100 weight percent of 25 of the  individual protein-medium-substrate  relationship.
the composition. The water content of the mixture can be    Although some ionic liquids stabilize proteins at higher tem
independently varied to provide the optimal combination of     peratures as shown by an increased transition temperature and
stabilization versus solubility. Water is not actually homog     enthalpy of unfolding, some do not. Many ionic liquids must
enous on a nanoscopic level, but consists of clusters of water    behydrated to some extent in order to stabilize proteins. They
molecules in low and high density arrangements. It is more  30 must partition the essential amount of water in the correct,
likely to form hydrogen bonds with other water molecules     organized fashion around the protein in order to maintain
than hydrophobic substances. When hydrophobic substances      activity. A certain amount of water is typically needed for
come in contact with water molecules, the water molecules     protein function and structure, but more water beyond the
form low density water (LDW) clathrate, or cage-like water     solvation layer at the surface may lead to destabilization. The
                                                                  35  role of hydration has been explored in a study of imidazoliummolecule structures around them. These highly ordered water
structures serve to decrease the entropy of the system.          based ionic liquids, which reveals an optimal 7.5% hydration
   In terms of a biological molecule, one can view entropy as     to reduce thermal denaturation, while 0% hydration lead to an
a measure of molecular disorder or a measure of how many     un-dissolved, kinetically trapped protein. Without wishing to
ways the molecule can arrange itself in order to absorb heat    be bound to a particular theory, ionic liquids may stabilize
energy as its temperature is raised to a certain temperature.  40  proteins by stripping off most of the water from the protein
Entropy, AS, is defined as the differential amount of heat     Surface, leaving only the essential water arranged in Small
transfer during an internal reversible process, 8Q, divided by      clusters.
the temperature, T, of the boundary at which the heat transfer     As stated before, proteins are generally stabilized by a
OCCU.S.                                                   combination of kosmotropic anions and chaotropic cations.
  Hydrophobic groups of a protein tend to pack together in 45 Without wishing to be bound to a particular theory, the anion
the protein core when in an aqueous solvent, allowing solvent     choice appears to have a stronger effect on the ability of an
water molecules more freedom of motion. This increases the     ionic liquid to stabilize a protein. Table 1 ranks differentions
entropy of the water, and thus of the whole protein-solvent    based on their B-coefficients. A higher B-coefficient indicates
system. Therefore, this hydrophobic effect is governed by the     a higher kosmotropicity. The ability of the anion to stabilize
second law of thermodynamics wherein the entropy of the  50  proteins is closely related to the Hoffmeister series (Micaelo
system increases during folding. It should be noted however,   & Soares, 2008).
that internal water does  exist, creating hydrogen bonds                   TABLE 1between charged interior, hydrophilic groups. This allows a
certain amount of necessary internal motion.                                B-coefficients of various ions used in ionic liquids (Kosmotropicity
   Protein stability is influenced not only by its interaction  55              increasing with increasingly positive B-coefficient).
with water, but by how any other co-solvent molecules           Anion            B-coef.      Cation              B-coef.
present interact with the water molecules around the protein.
Salts are ionic compounds that can be used as co-solvents in       PO-          O495     (CH),N'           O.123
aqueous protein liquid formulations. Ionic co-solvents may         HPO.             O.34     K                  O.O09
be classified as kosmotropic or chaotropic, depending on  60     CHCOOSO2              O.246O.2O6     MePy"Na                  O.O850.144
whether they encourage the formation of LDW or high den            Br                O.O33      Li                  O.146
sity water (HDW). “Kosmotropes' are compounds that inter        C                 O.OOS      EtPy"               O.228
act strongly with water molecules, and organize water mol          OTs             -O.O73      Ca2+               O.284
ecules  in a  typically  favorable manner around protein          PFBF              -O.093-0.21      Mg2+BuPy"              O.385O.396
molecules. “Chaotropes” are compounds that interact weakly  65                                      Al3+                O.744
with water molecules and disrupt the water molecule hydro
gen bonded network around protein molecules.

---

## Page 23

US 9,289,381 B2
                    11                                         12
  Other aspects of the present invention provide composi      tion. To protect against a detrimental pH change, a suitable
tions that comprise polypeptides. In some embodiments, the     buffer will accept or donate hydrogenatoms in order to keep
composition comprises, consists of, or consists essentially of    the pH stable. Its maximum buffering capacity should be at
a therapeutically active polypeptide, an acid, an organic salt     the pH at which the protein is structurally stable, should not
of the conjugate anion, and water. In other embodiments, the     act as a substrate, and should not be temperature dependent
composition comprises, consists of, or consists essentially of    (Branchu, 1999) (Ugwu & Apte, 2004).
a therapeutically active polypeptide, an organic  salt and       Sugars.                                                                    In nature, Sugars have been found to preserve proteins in awater. A base can, in some embodiments, be added to the                                                               glassy state, and this principle has been transferred to proteincomposition. In particular embodiments of the present inven  10                                                                cryopreservation. Trehalose, a disaccharide, stabilizes protion, the acid/salt ratio of the composition is such that proton                                                                     teins during freeze drying and high temperature exposure,activity   is  optimal  for  the  therapeutic  protein  and/or                                                      and acts as a protectant in temperature extreme resistantparenteral delivery.                                                             organisms. For example, addition of trehalose to a protein  Exemplary therapeutic polypeptides include, but are not                                                                 Solution increases the temperature at which the first stage oflimited to, enzymes and antibodies, such as monoclonal anti  15                                                     hen egg white lysozyme (HEWL) heat denatures (Hedoux, etbodies, polyclonal antibodies, humanized monoclonal anti
bodies, and non-glycosylated antibodies. Specific examples       al., 2006).                                                                   Polyols.of therapeutic polypeptides include, but are not limited to,                                                                Polyols (sugar alcohols), such as mannitol, glycerol, andinterleukin-2 and gelsolin.                                                          propylene glycol have also been determined to stabilize pro   In certain embodiments of the present invention, the com                                                                        teins, such as HEWL, as shown by a higher thermal transitionposition comprises, consists of, or consists essentially of                                                         midpoint temperature and enthalpy of unfolding (Cioci& al.,ionic liquids, such as, but not limited to, ethylammonium                                                          1996) (Singh & Singh, 2003). Two theories are proposed fornitrate and a therapeutic polypeptide.                                                                        this occurrence. Without being bound to either theory, the first   In other embodiments of the present invention, the compo                                                               Suggests that unfolding is less favorable when polyols aresition comprises, consists of, or consists essentially of choline 25  present. Mannitol, for example, is superior for preventingdihydrogen phosphate ("CDHP) and a therapeutic polypep                                                               aggregation. The second suggests that polyols form hydrogentide. Choline dihydrogen phosphate (CDHP) is a hydrophilic                                                      bonds with protein surface groups, restricting conformationalcombination of a biocompatible and kosmotropic anion,                                                        changes and protecting buried hydrophobic groups fromdihydrogen phosphate (dhp), and a cation, choline, which                                                          exposure to denaturation. (Singh & Singh, 2003)occurs naturally in biological systems (Scheme 1).           30   Amino Acids and Polyamines.
                                                 Amino acids have been used as additives to stabilize pro
Scheme 1: Structures of choline and dihydrogen phosphate (dhp).               teins in many studies (Cioci & al., 1996). For example, his                                                                   tidine  protects  proteins  by  acting  as  an  antioxidant.
                             O                      Polyamines, organic compounds having two or more amino
                                                                  35
   ~" HO1 No.                  groups,spermine,havea alsolow hadmolecularconsiderableweightstabilizingpolyamine,success.bindsWhento         \             OH            HEWL  both  thermal  stability and enzyme  activity  is
                         choline             dhp                      increased (Powroznik, 2004).                                                                     De-Stabilizers.
                                                             40   Urea and guanine hydrochloride are well known protein
  CDHP is not technically an ionic liquid, having a melting     denaturants.  Interestingly, at concentrations that are low
temperature slightly above 100° C., but is an organic salt.    enough not to lead to denaturation, these, unlike the non
Thermal gravimetric analysis shows it to be stable up to 200°     denaturant additives covered above, can enhance solubility
C. (Yoshizawa-Fujita, Fujita, MacFarlane, & Forsyth, 2007).     through increased hydrogen bonding between the denaturant
                                                                45CDHP is liquid at room temperature when hydrated to an    and the protein (Cioci& al., 1996) (Hirano, Hamada, Okubo,
optimal concentration of 80% w/w CDHP (that is, 80 parts    Noguchi, Higashibata, & Shiraki, 2007).
CDHP to 20 parts water by weight). Because of its large size,       Concentration Effects.
choline is usually considered to be quite a chaotropic cation,      While it is of interest to find a highly concentrated liquid
but the hydroxyl group increases its ability to hydrogen-bond     protein formulation to increase the ease and convenience of
                                                              50with water. The kosmotropicity of dhp is influenced by the     protein based drug administration, the effects of concentra
presence of free electrons on the oxygen atom, which     tion on proteinstability must be acknowledged. These effects
increases its ability to form hydrogen bonds with water mol     are not well understood, because most stability studies have
ecules. Kosmotropic effects are typically in reference to sol     typically been carried out on dilute (<1 mg/ml) concentra
utes dissolved in water, but it is assumed to be applicable or at     tions. Certainly proteins in physiological conditions are
least correlated, when water is acting as the solute and an  55  stable in high concentrations. Hemoglogin, for example,
ionic liquid is acting as the solvent (Fujita K., et al., 2007).       exists in human blood at 300 g/L (Guo, Ham, Robbins, &
                                                      Doug, 2006).
                      III. Methods of Preparation                               It is known that crowding of inert macromolecules, which
                                                   do not directly interact with the protein, may have a stabiliz
  Methods of preparing the compositions of the present  60 ing effect on proteins. Excluded volume theory explains this
invention are known in the art and described herein. In pre     as the result of the preference for a more compact, native
paring the compositions of the present invention, the follow     protein conformation in a crowded environment. It is not clear
ing factors or components can be considered, adjusted, and/or    whether this theory translates for high protein concentrations
added to the composition.                                      as opposed to high inert macromolecule concentrations (Guo,
  Buffering the pH.                                              65 Ham, Robbins, & Doug, 2006). Dilute protein solutions are
  As a protein interacts with its environment, it will release or     Stabilized primarily through intra-molecular interactions and
accept hydrogen atoms depending on the nature of the solu     hydration effects, while concentrated protein solutions may

---

## Page 24

US 9,289,381 B2
                   13                                        14
be stabilized through protein-protein interactions. Intra-mo     ing anemia. Growth hormone (e.g., human growth hormone)
lecular interactions in concentrated Solutions may be affected      is useful for treating and/or preventing conditions including,
by changes in hydration, Van der Waals forces, and covalent     but not limited to, Turner syndrome, chronic renal failure,
alterations (peptide and disulfide bonds, deamidation, oxida     Prader-Willi  syndrome,  intrauterine  growth  retardation,
tion). Guo, etal tested the stability of high concentrations (on     severe idiopathic short stature, maintaining muscle mass in
the order of 350 mg/ml) of lysozyme, hemoglogin, bovine    wasting due to AIDS, hort bowel syndrome multiple sclero
serum albumin, and bovine fibrinogen incomparison to dilute       sis, obesity, fibromyalgia, heart failure, Crohn's disease and
concentrations of 1 mg/ml. Spectroscopic and calorimetric     ulcerative colitis, burns, etc. Folicle stimulating hormone
measurements  revealed  a  protein  specific  relationship      (e.g. human folicle stimulating hormone) is useful for stimu
between stability and concentration. For example, the ther  10  lating the development of germ cells in both males and
mal transition midpoint temperature of lysozyme and BSA     females. Granulocyte-colony stimulating factor or G-CSF
decreased at the higher concentration (-5° C. and 23° C.      (particularly human G-CSF) is useful for stimulating the
respectively), while the transition temperature of hemoglobin    development of white blood cells (e.g., for treating neutrope
and fibrinogen increased (8°C. and 3°C., respectively) (Guo,     nia after chemotherapy in cancer patients).
Ham, Robbins, & Doug, 2006). It should be noted, however,  15   The therapeutically effective dose or treatment effective
that these proteins were dissolved in an aqueous solvent.    amount of any specific compound, the use of which is in the
Clearly, the protein concentration-stability relationship is not    Scope of present invention, will vary from compound to com
completely characterized and requires continued investiga    pound and patient to patient, and will depend upon the disor
tion.                                                        der being treated, condition of the patient and the route of
                                                                     delivery. As a general proposition, a dose of the active agent
               IV. Subjects and Administration                of from about 0.05 or 0.1 up to about 50 or 100 mg/kg subject
                                                     body weight is used.
  The present invention is primarily concerned with the treat      The present invention is explained in greater detail in the
ment of human Subjects, but the invention may also be carried     following non-limiting Examples.
out on animal Subjects, particularly mammalian Subjects Such  25
as dogs, cats, livestock and horses for veterinary purposes.                       Example 1
While subjects may be of any suitable age, the subjects are in
Some embodiments neonatal, infant, juvenile, adolescent,     By way of example, hydrated IL CDHP+water 80/20 has a
adult or geriatric Subjects.                                    proton activity equivalent to pH=~5.2 when present in dilute
                                                                30 aqueous solution. By addition of choline monohydrogen  The compositions of the invention include those suitable
for oral, parenteral (e.g., Subcutaneous, intramuscular, intra     phosphate, or choline hydroxide or any other slightly basic
dermal, or intravenous), topical (i.e., both skin and mucosal      salt such as choline tartarate, the proton activity of this can be
Surfaces, including airway Surfaces) and transdermal admin     adjusted to around neutral. A mixture of 4:1 CDHP+ Choline
istration, although the most Suitable route in any given case    hydroxide (with 20% water) molar ratio provides the equiva
will depend on the nature and severity of the condition being  35  lent of pH~7.2.
treated and on the nature of the particular active compound      Methods of measurement of proton activity in concen
which is being used.                                               trated acid/salt mixtures are not routinely available and we
   In general, the composition, including the active agent,     refer here to the equivalent dilute aqueous pH values obtained
may be packaged in Sterile form in a sterile container Such as    by diluting the medium with excess water and then perform
a vial, Syringe (for injection) etc. Depending upon the par 40  ing a traditional glass electrode measurement of pH.
ticular active agent (for example, IL-2 tends to have shorter        Stabilization of IL-2Using Choline Dihydrogen Phosphate
shelf lives in liquid form), the composition preferably has a    (CDHP).
shelf life in packaged form of at least 2, 3 or 4 days, up to 1,      Recombinant interleukin-2 (rIL-2) therapy has been dem
2 or 3 weeks or one month, or in some embodiments (particu     onstrated to elicit remission of several human tumors, includ
larly for more stable active agents) a shelf life in packaged 45  ing metastatic renal cell cancer (RCC) and malignant mela
form of at least one or two months up to 6 months or one to    noma. High-dose, bolus rIL-2 (i.v.) is approved in the US for
two years, or more, at a temperature of 37°C. “Shelf life’ has     these two indications, based on evidence of rL-2-induced
its conventional meaning in the art and refers to the time     durable cancer remission in a significant number of patients
period during which the active agent retains Sufficient activity    (5-10%) (Sparano, Fisher et al. 1993). The biological func
for accurate and effective administration thereof, and the  50  tions of IL-2 on anti-tumor effector cells have been exten
formulation retains sufficient stability (e.g., a single phase     sively investigated. IL-2 activates numerous critical cells in
Solution remains as a single phase solution) for accurate and     the immune system, acting as an autocrine factor to drive the
effective administration thereof at the recited temperature     expansion of tumor-specific helper and cytotoxic T cells (Th,
conditions.                                             CTLs), and as a paracrine factor acting on other immune cells
                                                                  55  (e.g., B cells, Natural killers, lymphokine associated killer   Disorders for which the compositions of the invention are
useful for treating are determined by the active agent con      cells) involved in killing tumorigenic cells (Bamford, Grantet
tained therein. For example: Interleukin-2 (e.g., human Inter       al. 1994; Waldmann, Dubois et al., 2001). More recently, IL-2
leukin-2) is useful for treating conditions including, but not    has been reported to be critical in maintaining “peripheral
limited to, cancer, viral infection, and as a vaccine booster or     tolerance' by enhancing T cell (Treg) survival and function.
                                                                  60adjuvant. Gelsolin (e.g., human Gelsolin) is useful for treat    One mechanism by which Treg cells contribute to the main
ing conditions such as cystic fibrosis (and particularly as an    tenance of homeostasis is by limiting IL-2 availability via
aerosol-delivered mucolytic therein). Antibodies (particu     constitutive, high affinity IL-2 receptor expression (Viguier,
larly monoclonal antibodies) are useful in treating or prevent     Lemaitre et al. 2004: Fontenot, Dooley et al. 2005).
ing conditions including cancer and autoimmune disease.       IL-2 is a single 133 amino acid polypeptide of molecular
                                                                    65 weight 15.5 kDa containing two sets of C-helical domainsInsulin, (e.g., human insulin) is useful for treating diabetes
(including both type I and type II diabetes). Erythropoietin     required for receptor binding/activation (Korner, Dettmer et
(e.g., human recombinant erythropoietin) is useful for treat       al. 1986; Bazan 1992). Storage of IL-2 in aqueous solution

---

## Page 25

US 9,289,381 B2
                  15                                        16
makes it susceptible to deamination of an asparagine residue     denatured or unfolded. An increase in the T   is generally
at position 88. At temperatures in excess of 44° C. IL-2     indicative of an increase in thermal stability. The area under
undergoes irreversible denaturation and aggregation in solu     the curve in a thermal scan can be integrated to determine the
tion (Sasaoki, Hiroshima et al. 1992). These physicochemical     enthalpy of unfolding, DH. We have observed an increase in
properties necessitate IL-2 to be freshly prepared prior to    both Tm and AH of lysozyme solutions as the protein is
clinical use. In addition, IL-2 activity is decreased in acidic     formulated with increasing amounts of CDHP consistent with
conditions (Ricci, Sarkar et al. 2003). Therefore bolus intra     increased thermal stability of the protein in the presence of
venous (i.v.) injections are commonly used. Following i.v.      this compound. We have also performed shelf-life studies of
administration, the pharmacokinetic profile of rL-2 is char    lysozyme formulated in CDHP/water mixtures (80% CDHP
                                                                    10acterized by a high plasma concentration that declines in a     wit/wt) and compared the activity to formulations stored in
bi-modal exponential form. The initial elimination phase of    0.1M sodium acetate, pH 4.0 (control) for 1-3 months at room
IL-2, due to extracellular distribution and renal elimination,     temperature. In these studies, the samples were diluted back
was reported to have a plasma half-life of 7-14 minutes. The     into buffer prior to analysis to determine if the protein was
second phase of elimination, which is attributed solely to       still in its native functional state. As observed in FIG. 2, the
                                                                       15renal excretion, is slower with an estimated terminal plasma   CDHP samples yielded a superior shelf-life as evidenced by
half-life of 85 minutes (Konrad, Hemstreet et al. 1990). To     retention of a higher fraction of folded protein (shown by a
compensate for rapid IL-2 elimination, high IL-2 doses (600,     higher Cp signal) at equivalent time points Enzymatic assays
000 U/kg) are repeatedly injected into patients (up to 6 injec    of functionality confirmed these observations.
tions at 8 hour intervals) undergoing IL-2 immunotherapy.       To determine if CDHP alters inherent IL-2 activity, we
   Ionic liquids are materials that have ionic characteristics,    performed a series of cell proliferation assays using the HT-2
yet are liquid at room temperature. Depending on the specific      cell line (a mouse Thelper cell line which requires exogenous
combinations of anions and cations in the mixture, the hydro     IL-2 to survive and proliferate). Preliminary analysis con
gen bonding and water miscibility can effectively be “tuned      firmed that CDHP (0-30 mM) was not cytotoxic in this cell
to the requirements of the solution (Yang 2009). In recent     line (data not shown). Subsequently, HT-2 cell proliferation
years several studies have reported the preservation and Sus  25 was stimulated using riL-2 (10 or 100U/ml) in the absence or
tained activity of biological enzymes and proteins in these    presence of CDHP (15 or 30 mM). To perform proliferation
ionic liquids (Feher, Major et al. 2007). In hydrophilic ionic     analysis HT-2 cells were stained with PKH26 (a red fluores
liquids, cations and anions play an important role in protein     cent dye that coats the cell membrane) prior to cell culture. As
and enzyme stabilization in the presence of water. A combi     the cells undergo division, the fluorescence detected (FACS)
nation of chaotropic (weakly hydrated) cations and kosmo  30  decreases logarithmically. Using this approach we demon
tropic (strongly hydrated) anions represent the best stabiliz     strated that HT-2 cell proliferation increased in a dose depen
ing solution studied to date (Zhao 2005). Ionic liquids are     dant manner with increasing exposure to r-IL-2 (FIG.3). The
traditionally synthesized from imidazolium-based cations     addition of CDHP to the culture medium did not significantly
and highly fluorinated anions. More recent developments     reduce rIL-2-induced HT-2 proliferation (FIG. 3), but actu
                                                                  35have demonstrated that ionic liquids can also be formulated     ally increased it.
from  salts, Sugars, amino acids and “biomolecules' that
already have approval for use as pharmaceutical excipients                 REFERENCES
(Fujita, Forsyth et al. 2006). Salts of the dihydrogen phos
phate anion mixed with Small quantities of water have dem       1. Angell et al. International Patent Application Serial No.
onstrated capabilities to dissolve moderate quantities of cyto 40   PCT/US2008/071254, published as WO 2009/015367 A2
chrome c, lysozyme, RNaseA, and cellobiose dehydrogenase      on Jan. 29, 2009.
(Fujita, MacFarlane et al. 2005; Constantinescu, D. et al.,      2. Baker, S. N., McCleskey, T. M., Pandey, S., and Baker, G.
2007). Furthermore the proteins were shown to retain struc       A., 2004, “Fluorescence Studies of Protein Thermostabil
tural integrity and biological activity under these conditions.         ity in Ionic Liquids. Chem. Commun. (Cambridge), 8, pp.
                                                                45    940-941. MEDLINE  first citation in articleIn addition, these proteins retained their structure at much
higher temperatures than are observed when formulated in     3. Fujita, K., MacFarlane, D. R., and Forsyth, M., 2005,
standard aqueous solutions.                                       “Protein  Solubilising and  Stabilizing  Ionic  Liquids.”
 A panel of choline compounds was initially screened for      Chem. Commun. (Cambridge), 38, pp. 4804-4806. MED
biocompatibility using a resaZurin fluorometric assay with     LINE  first citation in article
                                                                50mouse macrophages (J774) as the cell line. These data dem      4. Fujita, K., Forsyth, M., MacFarlane, D.R., Reid, R. W., and
onstrated that choline dihydrogen phosphate “CDHP had the         Elliott, G. D., 2006, “Unexpected Improvement in Stability
highest ECso. This compound was then tested for cytotoxicity      and Utility of Cytochrome C by Solution in Biocompatible
towards primary splenocyte cultures. Cell viability was then       Ionic Liquids.  Biotechnol, Bioeng.94.(6), pp. 1209-1213.
measured at 24h by trypan blue exclusion or with a resaZurin     MEDLINE  first citation in article
fluorometric assay. Splenocyte viability was not significantly  55  5. Byrne, N., Wang, L.-M., Belieres, J.-P., and Angell, C.A.,
altered at concentrations below 30 mM (FIG. 1). Interest       2007, “Reversible Folding-Unfolding, Aggregation Pro
ingly, at doses >30 mM Choline-DHP cytotoxicity markedly        tection, and Multi-Year Stabilization, in High Concentra
increased and was associated with a drop in culture medium        tion Protein Solutions. Using Ionic Liquids.” Chem. Com
pH below 7. To confirm the data parallel experiments were      mun. (Cambridge), 26, pp. 2714-2716. MEDLINE  first
performed using non-hematopoietic (B16-F10 melanocytes)  60    citation in article
cell lines from which similar results were obtained.                6. Cooper, A., Nutley, M.A., and Wadood, A., 2000, “Differ
   Proteins are generally active in the native, folded state and        ential Scanning Microcalorimetry.  Protein-Ligand Inter
lose function when they unfold. Exposing a protein system to        actions: Hydrodynamics and calorimetry, B. Z. Chowdhry
an increase in temperature perturbs the thermodynamic equi      and S. E. Harding, eds., Oxford University Press, Oxford,
                                                                    65librium between these two states. The denaturation tempera       N.Y., pp. 287-318. first citation in article
ture (or melting temperature) T  of a protein indicates the      7. Spinozzi, F. Ortore, M. G. Sinibaldi, R., Mariani, P.
point at which half the protein sample is folded and half is       Esposito, A., Cinelli, S., and Onori, G., 2008, “Microcalo

---

## Page 26

US 9,289,381 B2
                  17                                       18
   rimetric Study of Thermal Unfolding of Lysozyme in     formulations. Integration and analysis of this data enabled a
  Water/Glycerol  Mixtures: An  Analysis  by  Solvent     determination of the change in enthalpy (AH), entropy (AS),
  Exchange Model  J. Chem. Phys., 129, p. 035101, MED    and Gibbs free energy (AG) of protein unfolding. Enzyme
  LINE  first citation in article                                    activity/protein functionality was assessed using a bacterial
8. Fraser, K.J., Izgordina, E. I. Forsyth, M., Scott, J. L., and     lysis turbidimetric assay. This study revealed that 80% w/w
  MacFarlane, D. R., 2007, "Liquids Intermediate Between    CDHPhydrated with water improved shelflife of 10 and 100
   Molecular and Ionic Liquids: Liquid Ion Pairs? Chem.    mg/ml formulations of HEWL when compared to the best
  Commun. (Cambridge), 37, pp. 3817-3819. MEDLINE    known aqueous buffer as evidenced a higher folded fraction
   first citation in article                                    of protein in DSC scans and retention of enzyme activity over9. Ranke, J., Molter, K., Stock, F., Bottin-Weber, U., Poc  10                                                         5 months. There is also positive correlation between the per   Zobutt, J., Hoffmann, J., Ondruschka, B., Filser, J., and                                                           centage of CDHP in solution up to 40% w/w and the thermal   Jastorff,  B., 2004, “Biological  Effects of Imidazolium                                                                          stability of HEWL. The AH and AG of unfolding all increased   Ionic Liquids With Varying Chain Lengths in Acute Vibrio                                                               as the fraction of CDHP in solution was increased. These   Fischeri and WST-1 Cell Viability Assays,” Ecotoxicol,                                                                       15  results have positive implications for liquid formulation of  Environ. Saf, 58, pp. 396–404. MEDLINE  first citation   in article                                                      protein based therapeutics where a small increase in shelflife
                                                         of hours to days and retention of stability upon dilution in vivo10. Brown, D. M., Donaldson, K., and Stone, V., 2004,                                                    would significantly impact the cost and complications of this   “Effects of PM10 in Human Peripheral Blood Monocytes                                                             category of drugs.  and J774 Macrophages.” Respir. Res., 5(9), pp. 5-29. first
   citation in article                           HEWL was chosen as a protein in these experiments
11. Wright, E. L., Quenell, D.C., Suling, W. J., and Barrow,    because it is a well characterized protein which is widely
  W.W., 1996, “Use of Mono Mac 6 Human Monocytic Line     available. While 80% w/w CDHP was able to dissolve cyt C
  and J774 Murine Macrophage Cell Line in Parallel Anti     at 37 mg/ml, HEWL displayed limited solubility in this solu
  mycobacterial  Drug   Studies.   Antimicrob.  Agents     tion (Fujita, MacFarlane, & Forsyth, 2005) (Fujita, Forsyth,
  Chemother, 40(9), pp. 2206-2208. MEDLINE  first cita  25 MacFarlane, Reid, & Elliott, 2006). This was shown by a
   tion in article                                              spectrophotometric analysis performed in our lab by Dr.
12. Jiang, G., Woo, B. H. Kang, F. Singh, J., and DeLuca, P.     Katherine Weaver, seen in FIGS. 4, 5, and 6. A spectropho
   P., 2002, "Assessment of Protein Release Kinetics, Stabil     tometer, a Thermo Fisher Scientific Nanoprop 1000, was used
   ity and Protein Polymer Interaction of Lysozyme Encap     to detect the presence of aggregates in HEWL formulated at 1,                                                                30   sulated Poly(D.L-lactide-co-glycolide) Microspheres.  J.                                                                      10, and 25 mg/ml in 80% w/w CDHP. Aggregation is evi  Controlled Release, 79, pp. 137-145. MEDLINE  first                                                        dence that the protein is not in solution. In the Weaver experi
   citation in article                                         ment, a wide range of wavelengths from 220 nm to 750 nm13. Bradford, M., 1976, “A Rapid and Sensitive Method for                                                     were passed through the optimized column length and an  the Quantitation of Microgram Quantities of Protein Uti    absorbance was recorded for each. An increased absorbance                                                                  35   lizing the Principle of Protein-Dye Binding.  Anal. Bio                                                      from the baseline measurement was interpreted as hydrolysis  chem., 72, pp. 248-254. ISI MEDLINE  first citation in   article                                                   or aggregate formation. No absorbance was expected beyond
                                                       normal peptide bond and aromatic amino acid absorbance14. Shugar, D., 1952, “The Measurement of Lysozyme Activ                                                            ranges (190-230 nm and 280 nm  respectively),  thus an   ity and the Ultra-Violet Inactivation of Lysozyme. Bio
  chim. Biophys. Acta, 8, pp. 302-309. MEDLINE  first 40  increase in absorbance at wavelengths above this was taken as
   citation in article                                       an indication of protein aggregation. The results from the
15. Stolte, S. Arning,  J., Boffin-Weber, U. Matzke, M.,    Weaver experiment are shown in FIGS. 4, 5, and 6.
   Stock, F. Thiele, K., Uerdingen, M., Welz-Bierman, U.       FIG. 4 shows the Nano Drop results for 25 mg/ml HEWL
   Jastorff, B., and Ranke, J., 2006, “Anion Effects on the     formulations in 80% w/w CDHP or 0.1M NaOAc. Four 25
  Cytotoxicity of Ionic Liquids.” Green Chem..., 8, pp. 621  45 mg/ml formulations in 80% w/w CDHP are shown in solid
  629. first citation in article                           medium or lightgrey lines and triplicate 25 mg/ml formula
16. Nockemann, P., Thijs, B., Driesen, K., Janssen, C. R., Van     tions in a control buffer are shown in black dashed or dotted
  Hecke, K., Van Meervelt, L., Kossmann, S., Kirchner, B.,      lines. There is a definite absorbance increase in the 25 mg/ml
  and Binnemans, K., 2007, "Choline Saccharinate and Cho     samples formulated in 80% w/w CDHP from that of the
   line Acesulfamate: Ionic Liquids With Low Toxicities.  J.  50  control samples. This is indicative of a HEWL solubility limit
  Phys. Chem. B., 111, pp. 5254-5263. first citation in article    below 25 mg/ml.
17. Micaelo, N.M., and Soares, C.M., 2008, “Protein Struc       FIG. 5 shows the Nano Drop results for 10 mg/ml HEWL
   ture and Dynamics in Ionic Liquids. Insights from Molecu     formulations prepared in triplicate in 80% w/w CDHP or
   lar Simulation Studies.  J. Phys. Chem. B., 112, pp. 2566    0.1MNaOAc. The triplicates prepared in CDHPare shown in
  2572.                                                         55  Solid medium or lightgrey lines, and the triplicates prepared
18. Fujita et al. Choline dihydrogen phosphate. Acta Crystal     in a control buffer are shown in black dashed or dotted lines.
  lographica Section E Structure Reports Online ISSN 1600    There is an absorbance increase in the 10 mg/ml samples
  5368. 2009. P709.                                        formulated in 80% w/w CDHP, indicating aggregation. These
                                                                      results suggest the solubility limit of HEWL is below 10
                    Example 2                            60 mg/ml.
                                                            FIG. 6 shows the Nano Drop results for 1 mg/ml HEWL
  The objective of this study is to evaluate the stabilizing     formulations prepared  in  triplicate  in 80% w/w CDHP
effect of choline dihydrogen phosphate (CDHP), a biocom    (shown in solid medium or lightgrey lines) or 0.1M NaOAc
patible organic salt, on the long term thermal stability of hen    (shown in black dashed or dotted lines). There appears to be
egg white lysozyme (HEWL), a well characterized protein.  65 a slight absorbance increase in the 1 mg/ml samples formu
Microcalorimetry was implemented to determine the depen     lated in 80% w/w CDHP. Although excessive noise makes it
dence of specific heat (C) on temperature for a range of     difficult to confirm, this is indicative of a solubility limit of

---

## Page 27

US 9,289,381 B2
                  19                                      20
HEWL in 80% w/w CDHP less than 1 mg/ml. These results     tured). The raw data is be normalized to a buffer baseline as
are all consistent with a low HEWL solubility in 80% w/w     well as the protein concentration in the sample. Several
CDHP.                                                     parameters can be obtained from this information. The tem
  Because the solubility limit of HEWL in 80% CDHP was     perature at the peak of the endothermic unfolding event is the
so low, two types of formulations were tested in this body of    thermal transition midpoint temperature. A higher thermal
work. The first type was a dispersion of insoluble protein in     transition midpoint temperature is indicative of higher ther
which HEWL was formulated at 10 and 100 mg/ml in 80%    mal stability. The change in enthalpy is calculated from the
w/w CDHP. The thermal and functional stability of these     area under the peak. A larger enthalpy change indicates a
dispersions was evaluated monthly. The hydration level for     protein with more intact chemical bonds being broken. From
                                                                    10 these parameters, the entropic change during unfolding andthe 80% w/w CDHP was chosen to mirror the storage formu
lations for the 37 mg/ml cyt C (Fujita, MacFarlane, & For     the Gibbs free energy can be calculated.
syth, 2005) (Fujita, Forsyth, MacFarlane, Reid, & Elliott,       Microcalorimetry is a special kind of DSC, and refers to the
2006). A suitable stabilizing buffer had to be chosen to com      ability to measure very small heat flows such as those that
pare to 80% w/w CDHP. In a study comparing three buffers,     occur in very dilute protein Suspensions (<1 mg/ml). Using
                                                                       15  this technique we were able to evaluate the protein disperan acetate buffer, pH 4.0, has shown the highest conforma
tional stability, as evidenced by calorimetric measurements,     sions after they were diluted to the working range of the
when tested against glycine buffer, pH 2.5, and phosphate     microcalorimeter, which will be addressed shortly. This pro
buffered  saline  (PBS), pH  7.4  (Jiang, 2002) Optimal     tocol mimics the conditions a therapeutic protein stored in a
lysozyme solubility in an acetate buffer, pH 4, has been found     dispersion would encounter when diluted in vivo thus provid
to lie between 0.1M to 0.3M buffer (Forsythe & Pusey, 1996).     ing information on the condition of the protein following
Thus, a 0.1M sodium acetate (NaOAc) buffer at pH 4 was     storage and dilution back to physiologic osmolality levels.
chosen as a baseline comparison.                             Microcalorimetry was also used to directly evaluate the ther
  The nature of the dispersions was evaluated by two meth    mal stability of dilute HEWLaqueous solutions formulations
ods. Microscopic images were taken to evaluate the presence    with increasing amounts of CDHP, and therefore provide
of HEWL crystals, Secondly, centrifugation of the protein  25  specific thermodynamic information on the nature of the sta
dispersions was performed to achieve partial sedimentation.     bilization effects. Because the solutions required no dilution,
Complete sedimentation was not feasible because the densi     thermal stability due to the presence of CDHP could be
ties of HEWL and 80% w/w CDHP are so close, but the     directly evaluated.
presence of partial sedimentation confirms the solubility limit       B. Functional Stability Evaluation of Dispersions.
has been passed and indicates the presence of a dispersion.  30    Structural stability does not by itself guarantee that a pro
Protein concentration in the Supernatant and pellet was evalu     tein will still function as it should. Therefore, an assessment
ated to confirm that the dispersed phase was protein. The    of enzyme activity of HEWL must be used to fully character
second formulation type tested was solutions of 1 mg/ml     ize stability. Recall that HEWL preferentially hydrolyzes
HEWL in aqueous 0.1M NaOAc solvents with 0-40% w/w      B-1,4-glucosidic linkages between NAM and NAG of bacte
                                                                  35  rial cell walls. Micrococcus lysodeikticus has these types ofCDHP acting as a co-solvent. A concentration of 40% w/w
CDHP was chosen as a limit, because CDHP increases the    bonds in its cell walls, the breaking down of which is mani
Viscosity of aqueous solvents and there was concern about     fested as a decreased turbidity in such a bacterial solution.
damage to the microcalorimeter (to be discussed shortly). A    The rate at which this occurs can be monitored as a change in
formulation of 20% w/w choline chloride, a more traditional     absorbance, and can easily be correlated to enzyme activity.
                                                             40 This makes it an ideal assay for quantifying HEWL activity.salt, was used as a control. Thermal stability was evaluated
upon formulation. Microscopic images were used to confirm       Evaluation of Sterility in Dispersions.
the absence of HEWL in the solutions.                         Because the dispersion formulations are tested over a long
Evaluation of Protein Stability                                period of time, the risk for bacterial and fungal growth must
  A. Thermal Stability Evaluation of Dispersions and Solu    be minimized as an extraneous variable. The storage contain
tions.                                                          45  ers must be sterilized by exposure to UV light for at least 24
  Calorimetric measurement of protein unfolding is a well     hours, and the CDHP and buffer must be autoclaved for 45
established means of evaluating protein stability and kinetics.     minutes at least 248 F. Furthermore, there must be a way of
Differential scanning calorimetry, or DSC, is a method of     evaluating the presence of foreign contaminant growth. An
measuring the heat energy released or absorbed from a     enriched test broth specific for bacteria and fungi as described
sample over a range of increasing or decreasing temperatures.  50 by Parrow and coworkers can be used to eliminate the possi
If the sample is a protein solution, the protein undergoes a      bility that the protein is being denatured by bacterial or fungal
thermal unfolding event, releasing energy as  it unfolds. A    growth (Parrow, Burkholder, Deamer, & Ramsdell, 2005).
typical differential scanning calorimeter heats a sample (in      Confirming Sample Protein Concentration.
this case a dilute protein solution) in a sample cell at a con      There was some concern regarding the homogeneity of the
                                                                  55  dispersion formulations due to insolubility and the ability tostant rate and at a constant pressure. A reference cell contain
ing only the solvent undergoes the same treatment. Differ     accurately pipette Such viscous solutions. Uncertainty in the
ences in how much heat energy is required to be added to the      ability to precisely weigh out very Small amounts of protein
sample verses the reference cell in order to maintain them at     raised concerns in both the dispersions and solutions. There
the same temperature is measured. These differences can be     fore, the concentration in all evaluated Samples had to be
related to the constant pressure heat capacity of the protein in  60  Verified. The bicinchoninic acid protein assay is a spectro
Solution.                                                    photometric method for determining protein concentration
 A DSC thermogram plots the excess heat capacity as a    and will be used here.
function of temperature. The raw endotherm is the heat sig       Experimental Design and Statistical Analysis.
nature from the protein unfolding event, and in the case of an      The long term stability evaluation of 10 and 100 mg/ml
unfolding protein includes a pre-transitional baseline (before  65 HEWL dispersion in 80% w/w CDHP is a between subjects
the unfolding event), endothermic unfolding event, and post      factorial design with two factors, concentration and solvent.
transitional baseline (after the protein  is thermally dena    The levels of each factor are 10 and 100 mg/ml and CDHP and

---

## Page 28

US 9,289,381 B2
                  21                                       22
NaOAc, respectively. This experimental design is easily ana    15000 RPM for at least 75 minutes. BCA was performed on
lyzed with a two way ANOVA using the rate of decrease of the     the formulations before centrifugation to establish the exact
calorimetric or activity data over time as the dependent vari     concentration in each  triplicate. After centrifugation, the
able. The evaluation of HEWL as a function of CDHP con     Supernatant was removed and  its protein  concentration
centration can be evaluated using one way ANOVA (t-test).     assessed with a BCA assay. The pellet was re-suspended in an
Here there is one factor, the solvent, with 7 levels (0% w/w     equal amount of 0.1M NaOAc buffer, protein concentration
CDHP, 5% w/w CDHP, 10% w/w CDHP, 20% w/w CDHP,     assessed, and a mass balance was performed to confirm the
30% w/w CDHP 40% w/w CDHP, 20% w/w choline chlo      results. Because of similarly matched protein and CDHP
ride. Statistical analysis was performed with SPSS statistical     densities, complete sedimentation of HEWL particles was
                                                                    10  not the goal here. However, results did provide confirmingsoftware. Statistical significance was assessed on the CL=0.05
level.                                                      evidence that a dispersion was present.
   Material.                                                 D. Evaluation of Thermal Stability. Using Microcalorim
 HEWL and micrococcus lysodeikticus bacteria were pur      etry.
chased from Worthington Biochem (Lakewood, N.J.). CDHP    A MicroCal VP-DSC microcalorimeter was used to assess
was prepared by the Monash group by standard methods  15 thermal structural stability of all samples. Baseline repeat
(Fraser, Izgorodina, Forsyth, Scott, & MacFarlane, 2007)      ability was established with a minimum of 5 buffer-buffer
(Fujita, Forsyth, MacFarlane, Reid, & Elliott, 2006). All other     scans. HEWL dispersions were diluted with 0.1 M NaOAc
chemicals were purchased from Sigma Aldrich. The 2 ml     buffer (pH 4) so that the concentration fell close to 0.2 mg/ml,
silanized glass vials with cap and septa were purchased from    degassed for 6 minutes with a ThermoVac, loaded into the
National Scientific Company (Rockwood, Tenn.).                  cells, and scanned from 10° C. to 90° C./hour with a 15
  Methods.                                              minute pre-scan wait to allow for equilibration of the DSC.
  Because HEWL solubility was found to below in 80% w/w   HEWL solutions were tested similarly with no dilution of the
CDHP, two types of were tested. The first was a dispersion of    samples. Between samples, during the filling period of 15°C.
HEWL in 80% w/w CDHP. The second was solutions of     to 25°C., the sample cell of the DSC was flushed with at least
HEWL in aqueous buffer with increasing amounts of CDHP.  25 25ml distilled HO, then at least 15 ml NaOAc to ensure no
  A. HEWL Dispersion Formulation.                       sample residue remained behind. Thermal profiles, enthalpy
  To evaluate the long term stability of dispersions of HEWL     changes, and transition temperatures were obtained with Ori
in a mildly hydrated CDHP solution, HEWL was formulated     gin software.
in triplicates in 80% w/w CDHP (aq) 10 and 100 mg/ml, by        E. Micrococcus Lysodeikticus Turbidimetric Assay.
adding the hydrated CDHP directly to lyophilized protein.  30    Functional integrity of lysozyme was determined accord
The samples were formulated in 2 ml silanized glass vials to     ing to Shugar, which is based on the decrease in turbidity of
reduce protein-surface interactions, covered with cap and     the Substrate, micrococcus lysodeikticus, Suspension (Sugar,
septa, wrapped with parafilm to ensure no drying out of the     1952). The micrococcus lysodeikticus turbidimetric assay
sample, and stored away from Sunlight. They were stirred for     takes advantage of the ability of HEWL to preferentially
at least 24 hours until a homogeneous distribution of protein  35 hydrolyze B-1,4-glucosidic linkages between NAM and NAG
was obtained. To assure no bacteria growth in the samples,     of bacterial cell walls. A 0.3 mg/ml suspension of the bacteria
both buffer and CDHP were autoclaved for 45 minutes at 248      in 0.1M phosphate buffer (pH 7) was prepared. Serial dilu
F. before formulation. The 35 silanized vials were exposed to     tions of stored proteins were prepared so that the absorbance
UV light for 24 hours to ensure sterility. Control samples at    decay fell between -0.015 and -0.04 AA450/min. At time
equivalent concentrations were also prepared in triplicates in 40  Zero, 10u  of the bacteria suspension were added to 290 uL
0.1M NaOAc buffer (pH4). Samples were tested for thermal    of sample in a 96 well plate. Kinetic absorbance measure
stability via microcalorimetry and functional activity via the    ments were taken every 6-10 seconds for 2 minutes at 450 nm,
micrococcus lysodeikticus assay at monthly intervals.          and a slope was determined. Only those slopes with a linear
  B. HEWL Solution Formulation.                             regression coefficient of at least 0.98 were accepted. The
                                                                45 HEWL was dissolved at 1 mg/ml in 0, 5, 10, 20, 30, and    AA450/min was used to determine enzyme units (EU) of
40% w/w CDHP in 0.1M NaOAc. Using a CDHP molecular     activity per mg protein.
weight of 201 g/mol,  this  is 0, 248.76, 497.52, 995.02,         F. Test for Sterility. Using Culture Broth Specific for Fungi
1492.54, and 1990.05 mMCDHP. A 1 mg/ml HEWL control    and Bacteria.
solution was formulated similarly in 20% choline chloride.      Each storage sample formulation was tested at 4 months for
All samples were prepared in triplicate.                       50  bacteria and fungi contaminants as described by Parrow et al.
  C. Confirmation of the Nature of Dispersion and Solution    Analiquot of each sample formulation was inoculated with an
Formulations.                                                enriched test broth (0.5 g/L bactopeptone, 0.5 g/L yeast
   Solubility of HEWL in both formulation types was evalu      extract, 0.5 g/L glucose) in 20 ml broth tubes. Positive and
ated to confirm the presence of a dispersion or a solution. The     negative controls were also prepared. Samples were observed
                                                                  55  after 7-10 days incubated in darkness at room temperature fornature of the HEWL dispersions in 80% w/w CDHP was
evaluated by microscopy and sedimentation analysis. The    obvious signs of contamination, manifested as extreme broth
nature of the HEWL solutions was evaluated by microscopy.     cloudiness.  (Parrow,  Burkholder, Deamer, &  Ramsdell,
HEWL formulated at  1, 10, and 100 mg/ml in 80% w/w    2005)
CDHP and 0.1M NaOAc were observed using Bright field      G. Protein Concentration Determination with Bicincho
microscopy, and the appearance of any crystals observed and  60  ninic Acid Assay.
noted. The presence of any CDHP crystals was also noted.        Protein concentration for each tested aliquot was validated
Lyophilized HEWL and non-hydrated CDHP crystals were    with a bicinchoninic acid (BCA) protein assay kit was pur
also observed under similar conditions to help with morpho     chased from Sigma Aldrich. A standard curve generated by
logical identification. Images were taken using SlideBook.     preparing a serial protein dilution series from freshly recon
                                                                    65Sedimentation analysis was also used to evaluate the protein      stituted 2 mg/ml HEWL standards formulated in triplicate in
dispersions. HEWL was formulated at 10 and 100 mg/ml in    0.1M NaOAc buffer (pH4). Because different proteins may
80% w/w CDHP in triplicate. Samples were centrifuged at     exhibit slightly different behavior in the BCA assay, the

---

## Page 29

US 9,289,381 B2
                  23                                      24
bovine serum albumin (BSA) protein concentration standard     not useful for establishing solubility limits, it does confirm
was not used to calculate the serial dilution series as pre-     that the solid phase is predominantly HEWL, as expected.
scribed by Peirce.                                               B. Solutions of HEWL (1 mg/ml) with Increasing Concen
  20 ul aliquot samples of each concentration were added to     trations of CDHP.
280 ul of the working reagent in a 96 well plate, incubated at  5    All samples of HEWL prepared at 1 mg/ml in 0.1MNaOAc
60° C. for 30 minutes, and cooled to room temperature.     containing 0 to 40% w/w CDHP were clear by eye. Bright
Absorbance measurements were made at 570 nm on a micro-      field microscopy also revealed no crystal formation in any
plate reader. The working range of this assay is 5-2000 g/ml.     sample, indicating that HEWL is in solution at this concen
Data and Analysis                                                  tration in these formulations.
   Solubility of HEWL in CDHP.                               10  Stability of HEWL in CDHP. Dispersions of HEWL in 80%
  Based on the solubility data acquired previously in our lab,   CDHP
two types of formulations were prepared: a) Protein (HEWL)      A. Thermal Stability of HEWL Dispersions in 80% CDHP.
dispersions prepared in 80% w/w CDHP with CDHP as the       Microcalorimetry was used to evaluate the structural integ
predominant co-solvent and b) solutions of protein (HEWL)      rity and thermal stability of HEWL after storage as dispersion
in 0.1M sodium acetate, with various amounts of CDHP as a  15  at 10 and 100 mg/ml in 80% w/w CDHP. All formulations
solute. Experiments were performed to verify the nature of    were diluted to 0.1-0.5 mg/ml for testing. This allows one to
these compositions.                                         observe how well protein thermal stability and structural
  A. Dispersions of HEWL in 80% CDHP                        integrity is maintained following storage and then dilution
  Based on data acquired on lysozyme solubility in 80% w/w     into a solution of similar composition as the environment of
CDHP, it was observed that the solubility limit of HEWL was  20  the body. FIG.7 show the averaged DSC traces for the HEWL
less than  1 mg/ml in these formulations. Therefore, higher     stored over a period of 5 months at 10 and 100 mg/ml in either
HEWL concentrations were expected to form a dispersed   80% w/w CDHP or 0.1MNaOAc. At the time of formulation,
solid phase in 80% w/w CDHP. To verify that CDHP was not     there was no apparent immediate denaturation in the CDHP
precipitating out of solution and replacing the protein as the     formulations as evidenced by similar peaks between the con
dispersed phase, two methods were used  to assess  the  25  trol and CDHP. All peaks at time zero are sharp and well
samples. Samples were photographed at high magnification     defined, suggesting a highly cooperative, two state reversible
under a microscope, and the morphology of the crystals     unfolding process. Not Surprisingly, there is a significant loss
observed were compared to pure crystals (not shown).         of thermal stability in both control samples over the first
  The similarities of HEWL crystals are apparent when    month as shown by a decreased area under the peak (i.e. a
observed under bright field microscopy in  1, 10, and 100  30 decrease in enthalpy change of unfolding). The area under the
mg/ml HEWL in 80% w/w CDHP formulations. No crystals    peak of the HEWL formulated in CDHP decreases only
were seen in similar formulations in 0.1M NaOAc, showing     slightly over the first month, then begins to mirror that of the
that the solubility limit of HEWL is above 100 mg/ml in 0.1M     control samples in the third and following months. The
NaOAC.                                HEWL formulated in 80% w/w CDHP appears to maintain a
  The second approach to verify these sample compositions  35  superior shelf life over the first two months compared to the
was to determine the amount of protein in the dispersed phase     buffered counterparts.
                                              TABLE 2
                                                             Enthalpy of unfolding of HEWL (cal/mol) stored at 10 and
                                                        100 mg/ml in CDHP or 0.1M NaOAC over a period of 5 months.
                                                                    Choline dhp                            NaOAC
                                                 Triplicate              Time (months                             Time (months

                            mg/ml   Number     O         1     2      3      4       5      O         1     2      3      4        5

                                    10           1      101700 908SS 79236 SS227 47358   36900  10253O  6732O S281 2 4O734  36931.6   20900
                                           2      108300  8961O 79113 63418 S1147   43OOO  105480  S877O S6880 4O690  26956.8   22400
                                              3      102OOO 90932 80771 S6640 46720.8 36900  99490  71640 S3856 39168  24870.6   18400
                                 100           1      107100  8997O 75132 SS23S  45229.S. 38900  101.140  62010 58.311 46.606  3O888.9   26800
                                           2      100700  89606 76824 S7272  4558O.S. 364OO  1052OO  S6610 60858 46SO6  32O71.77  29.100
                                              3      108300  87876 77544 S4900 49716   393OO  1082OO  71973 S4729 46224  29802.6   23900

after separation of the Solid and liquid components by cen-      The enthalpy of unfolding is found by integrating the curve
trifugation. To achieve separation of these components, solu-     generated by plotting the Surplus heat capacity at constant
tions were centrifuged for 75 minutes at 15000 RPM, about  55 pressure of the sample protein solution against the tempera
10% remained in the supernatant. Both the decanted super-      ture. FIG.8 shows the trend of this enthalpy change over time
natant and the pellet, which was re-suspended in buffer, were    and Table 2 shows the enthalpy data for the 10 and 100 mg/ml
analyzed for protein content. It was observed that ~90% of the     formulations.
formulated protein was contained in the pellet. The remaining      At 1 month, enthalpis change during unfolding decreases
about 10% of the formulated protein was found in the super-  60 on average to 64 and 60% of the maximum, respectively, in
natant. Because the densities of 80% w/w CDHP and HEWL     the 10 and 100 mg/ml HEWL control formulations, while
                                                           only decreasing to 87 and 85% if the maximum in the 80%are so similar, the centrifugation time and rate was probably    wfw CDHP formulations. This indicates that more of the
not adequate enough to completely sediment the protein.   HEWL is kept structurally intact in the 80% w/w CDHP
Although the Supernatants appeared clear it is possible that  65  formulations, leading to a greater release of heatenergy when
there are sub-visible particles of lysozyme in the supernatant     thermally denatured. Using an exponential curve fit in Origin
that resist sedimentation at this rate. Although this approach is    by OriginLab Corporation, an average enthalpic half life of

---

## Page 30

US 9,289,381 B2
                 25                                      26
3.76 months and 3.59 months was calculated for the 10 and     formulations, but remained fairly constant in the control for
100 mg/ml HEWL in 80% w/w CDHP, as opposed to only     mulations as seen in FIG. 11. Because HEWL is in a dispersed
1.99 and 2.1 months for the 10 and 100 mg/ml HEWL in 0.1M    phase in the 80% w/w CDHP formulations, the sample vari
NaOAc. A two way ANOVA comparing the decrease in     ability is inevitably higher. Beyond 3 months there appears to
enthalpy overtime revealed no significant difference between    be a trend towards less total protein in the extracted samples.
formulation concentrations for each solvent. However, a sig    While  it is possible that this could be due to progressive
nificant statistical difference (P=0.002) was found between    adherence of the Solid phase to the vial, there is some possi
lysozyme formulated in hydrated CDHP verses NaOAc, with      bility that the protein has chemically degraded to the extent
the ionic liquid having a higher stabilizing effect on the pro     that it is not measurable by standard BCA methods. Because
tein.                                                                10 of this net loss of protein at extended storage times, the
  FIG. 9 shows the thermal transition midpoint temperature     estimated half-life in CDHP is over-estimated. Further work
change over time. If the protein is not irreversibly changed as    would be necessary to achieve an appropriate correction.
a result of storage and dilution, one would expect to see no     Independent of the reason for the protein loss, the BCA
change in T. A decreased T would suggest that the protein     results indicate that storage beyond 2 months in 80 wt %
                                                                       15 CDHP is not recommended.has decreased in thermal stability as a result of the storage and
processing. At the time of formulation, the T  of all formu      D. Sterility Results.
lations are the same, indicating no irreversible change in both      About 100 of each sample formulation was used to inocu
80% w/w CDHP and 0.1M NaOAc formulations upon for      late an enriched culture broth and observed after several days.
mulation and dilution. The thermal transition midpoint tem    As seen in FIG. 12 no contamination was present in any
peratures, T  of all samples progressively decreased over     formulation. The positively marked vial is the positive con
time as seen in FIG.9, with the largest decrease in the control      trol, the negatively marked vial is the negative control, the vial
formulations. The T  of HEWL formulated in 80% w/w    marked IL is one of the CDHP formulations, and the vial
CDHP does not change appreciably, dropping less than a    marked NaA is one of the control formulations. The positive
degree, while the T  of the control formulations drops     control  is  clearly  cloudy, indicating bacterial or fungal
                                                                  25between one and two degrees over 5 months. A two way     growth. The negative control was identical to all otherformu
ANOVA comparing the 10 and 100 mg/ml transition tem      lations. Therefore, bacterial or fungal contamination can be
perature data revealed a significant difference between sol     ruled out as a variable in the structural and functional stability
vents (P<0.001, P=0.001, P-0.001 at 1, 3, and 4 months,    of the stored formulations.
respectively). The thermal transition data for these dispersed     Solutions of HEWL (1 mg/ml) in 0-40% w/w CDHP Solu
formulations can be found in Table 3.                            tions
                                TABLE 3
                          Thermal transition midpoint temperature of HEWL stored at 10 and 100 mg/ml
                                               in CDHP or 1.OM NaOAC over a period of 5 months.
                                         Choline dhp                                  NaOAC
            Triplicate                   Time (months                                   Time (months

 mg/ml   Number     O          1       2        3      4        5       O           1       2        3      4        5

    10          1      346.74   346.62   346.81   346.52   346.43   346.37   346.77   345.93   345.9    345.9    345.1    345. OS
             2       346.71   346.7S   346.39   346.3S   346.S    346.21   347.14   345.94   345.8    345.48   345.21   345.15
              3       346.71   346.7    346.84   346.98   346.47   346.27   346.68   345.79   345.8S   345.72   345.17   345.13
   100          1     34745   346.41   346.42   346.39   346.3    346.29   346.92   345.92   345.78   345.79   345.47   345.39
             2      347.OS   346.54   346.43   346.39   346.3S   346.02   346.45   346.17  346      345.9    345.41   345.39
              3        347.1.1   346.44   346.47   346.37   346.37   346.3S   347.06   345.84   345.69   345.66   34551   345.41

  B. Functional Stability of HEWL Dispersions in 80%      A. Thermal stability of HEWL Solutions.
CDHP.                                                     FIG. 13 shows the DSC Scans of HEWL formulated in
   Functional integrity of the protein was measured by a tur     increasing concentrations of CDHP with a 20% w/w choline
                                                                50  chloride solution used as a control. The thermal transitionbidimetric assay. As indicated in FIG. 10, lysozyme formu
lated in NaOAc degrades faster at all concentrations. This    midpoint temperature clearly increases with an increasing
assay requires dilution of samples to about 0.03-0.05 mg/ml,    amount of CDHP, but the choline chloride formulation does
which, as for the microcalorimetric experiments, will reveal     not have the same stabilizing effect on the HEWL as the
more about if 80% w/w CDHP stabilizes HEWL during stor     corresponding 20% w/w CDHP formulation. These results
age and less about if CDHP plays a direct role in enzyme  55  indicate that the CDHP interacts with the protein or the co
activity changes. A two way ANOVA shows that the decrease     Solvent in Such a way as to stabilize the protein structure, an
in enzyme activity over time difference between solvents is     effect which is not due to the choline ion alone. Also, the
statistically  significant  (P=0.001). The enzyme  activity     specific heat capacity of the formulations increases with an
reflects the functional stability, and appears to mirror the     increasing amount of CDHP. This suggests that the CDHP
functional stability results from the calorimetric experiments.  60  interacts with the protein or the protein co-solvent relation
There is not a statistical difference in enzymatic activity     ship in Such a way as to highly organize the protein structure
between different protein concentrations in the same solvent.     so as to better absorb heat energy. This would furthermore
  C. BCA Assay.                                               yield a higher enthalpy of unfolding in solutions with a higher
  The BCA assay was used to ensure that the calorimetric     concentration of CDHP, which is seen.
and activity measurements were correctly normalized to the  65    FIG. 14 shows that increasing amounts of CDHP in the
exact protein content within each aliquot. Over time, the     formulation results in a higher thermal transition midpoint
expected concentration in the aliquots decreased in the CDHP     temperature. Unlike the storage formulations, these samples

---

## Page 31

US 9,289,381 B2
                 27                                      28
were formulated at 1 mg/ml, a concentration that requires no     function of % w/w CDHP in 0.1M NaOAc as the enthalpy
further dilution for microcalorimetry. Therefore, one may    change and transition temperature. Average entropic data was
conclude CDHPappears to enable HEWL to resist to thermal       fit in Origin 8.4 with the following exponential growth fit:                                                  y=277.43+19.81e’’, where y  is the entropy change ofdenaturation. This data was fit in Origin 8.4 with the following exponential growth fit: y=344.95+3.33e°7', where y is     unfolding in cal/mol and X is the weight percent of CDHP.                                                                     Typically, the unfolded protein has much higher conformathe thermal transition midpoint temperature in Kelvin and X is                                                                     tional entropy than the folded conformation. In the solutionsthe weight percent of CDHP.                                                          with a higher concentration of CDHP, this difference is more
  FIG. 15 indicates that there is a small increase in enthalpy     exaggerated. While this is not a stabilizing entropic effect, the
of unfolding as the concentration of CDHP is increased in the  10  enthalpic change of unfolding is large enough to counteract
Solution. More energy is being released as the protein unfolds,      this, as shown in the increasingly unfavorable Gibbs free
which indicates an increase in the ability of the protein to     energy change of unfolding with higher concentrations of
store heatenergy. This may suggest direct interaction with the    CDHP, as will be shown next.
CDHP. Ligand binding could aid instructural stabilization by       FIG. 18 shows the Gibbs free energy of unfolding at room
creating more bonds within the protein. It could also organize  15 temperature of HEWL (1 mg/ml) solutions in 0, 5, 10, 20, 30,
water molecules in Such a way as to create a more stable    and 40% w/w CDHP in 0.1MNaOAc. The free energy change
hydrogen bond network with the protein. According to Rob     for an unfolding process becomes more unfavorable with
inson, et al., more polar groups on a protein Surface forming     higher concentrations of CDHP, thus stabilizing the folded
hydrogen bonds with water molecules gives rise to higher     protein. The relationship between Gibbs free energy change
enthalpic change (Robinson & Cho, 1999). This correlates    of unfolding at room temperature was fit in Origin 8.4 with the
with the theory that CDHP acts as a kosmotrope to favorably     following   exponential   growth     fit:   y=13340.678+
affect protein hydration.  Enthalpic data was  fit with an    1618.283e'7, where y is the Gibbs free energy change of
adjusted correlation coefficient of 0.9906 with the following     unfolding in cal/mol and X is the weight percent of CDHP.
exponential growth fit:y=96031.95+7507.06e''', wherey      Gibbs free energy of unfolding becomes more positive
is the enthalpy change of unfolding in cal/mol and X is the  25 with increasing concentrations of CDHP, indicating that the
weight percent of CDHP.                                     folded conformation becomes more energetically favorable at
  FIG. 16 shows an increase in the entropic change as the    room temperature. All thermodynamic parameters for the
protein unfolds, following a similar exponential trend as a   HEWL solutions are found in Tables 4 and 5.

---

## Page 32

---

## Page 33

US 9,289,381 B2
                  31                                       32
                      TABLE 5
        Gibbs free energy change at 25 C. of triplicates of 1 mg/ml HEWL in increasing
            amounts of CDHP and 20% ww choline chloride. Units are in cal/mol.

                                             Formulation

                                                            20% Wiw
         0% Wiw   5% wiw   10% wiw  20% Wiw  30% twiw  40% wiw    Choline
  Triplicate   CDHP    CDHP    CDHP   CDHP    CDHP    CDHP     Chloride
       1       1SO3O.24   14730.02   15295.08   17754.96   224O7.08   24OO1.8    12725.42
     2      1SS77.94   15918.62   15052.44   18362.96   20716     2S634     13397.9
     3       14496.3    15480.14   16934.42   17405.26   17097.4    23830.4    12597.32

   B. BCA Concentration Verification Assay.                    15  ing the protein. Therefore, lysozyme may be indirectly stabi
   Verification of sample concentration using the BCA was on     lized by CDHP purely because solvent accessibility  is
all solutions of HEWL (1 mg/ml) in 0-40% w/w CDHP.     decreased at these concentrations.
Sample variability was minimal.                              There may also be a solvent viscosity effect on protein
Discussion                                                  conformational stability in these solutions. Ansari, etal char
  Two types of formulations were investigated in this work:     acterized myoglobin conformational change as a function of
high concentration protein dispersions and low concentration     Solvent viscosity. They defined an exponential decay function
protein solutions. In the case of the dispersion formulations,     relating the rate constant of conformational change with Sol
HEWL was prepared at 10 and 100 mg/ml in 80% w/w CDHP.     vent viscosity. Between 0.1 and 1 cB, only internal protein
This particular concentration of CDHP was shown to be opti     protein  friction  predominated  the  rate  constant  value.
mal for achieving a multi-year shelf life of cyt C at protein  25 Between 1 (the viscosity of water at room temperature) and
concentrations up to 37 mg/ml (Fujita, Forsyth, MacFarlane,     10 (the viscosity of kerosene at room temperature), internal
Reid, &  Elliott, 2006). Because HEWL was  relatively     protein-protein and friction exerted by the solvent on the
insoluble in 80% w/w CDHP, dispersed protein solutions     protein Surface caused a large decrease in the rate constant to
were prepared instead of protein solutions. Dispersions are   80% (at 1 cF) and 12% (at 10 cB) of the original. At higher
readily soluble compared to bulk lyophilized formulations  30  solvent viscosities from 10 to 1000 cp (the viscosity of castor
(Krasnyuk Jr., 2009). This can positively impact the time      oil at room temperature) where friction between the solvent
required to prepare solutions at point-of-use, which is very    and protein surface predominated, the rate constant decreased
important for emergency therapeutics Such as Factor VIII     exponentially to nearly 1% (at 1000 cB) of the original rate
used for hemorrhaging (Chuansumrit, et al., 2000). In the     constant (Ansari, Jones, Henry, Hofrichter, & Eaton, 1992).
case of the low concentration solutions, HEWL was dissolved 35 80% w/w/CDHP has a room temperature viscosity of 440 cF
at 1 mg/ml in increasing ratios of 0.1M NaOAc to CDHP. In     (similar to motor oil) (Fujita, Nakamura, Igarashi, Sameima,
the range of 0-40% w/w CDHP, HEWL was fully soluble at   & Ohno, 2009) and is therefore well in the range of solvent
this concentration.                                                Viscosity dominating effects on protein kinetics. The Viscos
  A. Protein Dispersions.                                             ity of the protein formulations is undoubtedly higher than
                                                             40 HEWL dispersions stored in 80% w/w CDHP remained   80% w/w/CDHP alone.  It stands to reason, without being
more stable over time as indicated by a higher thermal tran    bound to a particular theory, that viscosity as well as HEWL
sition midpoint temperature, enthalpy change of unfolding,     insolubility contributes to the enhanced shelf life seen in the
and enzyme activity compared to control at all points over     stored dispersed formulations. This is likely true in the case of
time. One can equate this to an increased shelf life of HEWL     the previously reported stabilization effects of cyt C as evi
in comparison to the control. Without being bound to a par  45 denced by a shift in the thermal transition midpoint tempera
ticular theory, the 80% w/w formulations are most likely     ture from 80 C.  to 120 C.  (Fujita, Forsyth, MacFarlane,
stabilized due to insolubility at this hydration level or due to     Reid, & Elliott, 2006) (Fujita K., et al., 2007).
the extremely viscous nature of the formulation.                  B. HEWL Solutions.
  The dispersed nature of these formulations was supported      The solutions of 1 mg/ml HEWL in 0, 5, 10, 20, 30, and
by the presence of HEWL crystals in the 80% CDHP formu  50 40% w/w CDHP revealed an increase in thermal stability as
lations at 20x and a high protein content in the sedimented    evidenced by an increase in the T. Viscosity may play a role
phase. These results are consistent with the work performed    here as well. Ansari, etal has shown an exponential decrease
in our biostability lab by Dr. Katherine Weaver using the     in protein conformational dynamics as solvent viscosity
NanoDrop 1000 to probe solubility of 1, 10, and 25 mg/ml     increases from only 1 to 10 cp (Ansari, Jones, Henry, Hof
HEWL formulations in 80% w/w CDHP and 0.1M NaOAc.  55  richter, & Eaton, 1992). The thermal transition midpoint tem
The buffered solutions appeared to be in solution, while the     perature of HEWL in this study has also been shown to follow
10 and 25 mg/ml formulations in 80% w/w CDHP displayed    an exponential trend with the increase in CDHP. This expo
aggregation. (The solubility of the HEWL at 1 mg/ml in 80%     nential relationship Suggests the thermal stability imparted by
CDHP were inconclusive due to excessive noise in baseline     the CDHP may be due to the increased solvent viscosity.
readings, but the results suggest that the Solubility limit may  60   The thermal stability of 1 mg/ml HEWL formulated in
be less than 1 mg/ml).                                          increasing concentrations of CDHP may also be due in part to
   Insoluble protein may be stabilized because it is trapped in     direct protein-CDHP interaction, but it seems more likely to
a semi-lyophillized form. In other words, rather than a solu    be due to an ability of CDHP to organize the hydration water
tion, CDHP arranges crystallized lysozyme in a heteroge     in a favorable manner for the folded protein. Robinson, et al
neous dispersion or Suspension. The removal of water from  65 summarizes the effect of water molecules of the hydration
the lyophilized protein limits its flexibility, thus dramatically      shell around proteins and unfolding and the thermodynamic
decreasing the entropy of the system and effectively stabiliz     contribution, and the increased enthalpic change of unfolding

---

## Page 34

US 9,289,381 B2
                  33                                      34
with increasing amounts of CDHP may be due to an ability of      5. Byrne, N., Wang, L.-M., Belieres, J.-P., & Angell, C. A.
CDHP to favorably impact protein hydration, as indicated       (2007). Reversible foldingunfolding, aggregation protec
previously.                                                             tion, and multi-year stabilization, in high concentration
  Conclusions.                                                      Solutions, using ionic liquids. ChemComm, 2714-2716.
                                                                       5  The stability of a model protein, lysozyme, in hydrated      6. Chaplin, M. (2008, Sep. 26). Protein Hydration. Retrieved
CDHP has been quantified. The thermal stability of HEWL       Oct. 2, 2008, from Water structure and science: http://
formulated at 10 and 100 mg/ml in 80% w/w CDHP was       www.lsbu.ac.uk/water/sitemap.html
evaluated by microcalorimetric methods. These formulations      7. Chuansumrit, A., Isarangkura, P., Angchaisuksiri, P., Sriu
were shown to have a longer shelflife than control samples in      domporn, N., Tanpowpong, K., Hathirat, P. et al. (2000).buffer. The structural and functional half integrity of the pro  10                                                                Controlling acute bleeding episodes with recombinant factein in 80% w/w was significantly superior to the control                                                                     tor VIIa in haemophiliacs with inhibitor: continuous infuformulations over the first two months of storage as evidenced                                                                  sion and bolus injection. Haemophilia, 6 (2), 61-65.by a higher thermal transition midpoint temperature, enthalpy                                                                           8. Cooper, A. (2000). Heat Capacity of hydrogen-bondedchange of unfolding, and enzyme units per mg. Activity mea                                                                       15    networks: an alternative view of protein folding thermodySurements were consistent with the thermal analysis. Because                                                              namics. Biophysical Chemistry, 85,25-39.these concentrated protein formulations had to be diluted                                                                           9. Cooper, A., Nutley, M.A., & Wadood, A. (2001). Proteinwith a control buffer by factors on the order of at least 100 and                                                                 ligand interactions: hydrodynamics and calorimetry (Vol.1000, respectively, for testing, these results mirror what
would happen to the protein upon dilution and in vitro admin         1). New York, N.Y.: Oxford University Press.
istration. It is possible that the increased shelf life of HEWL     10. Forsythe, E. L., & Pusey, M. L. (1996). The effects of
dispersions in 80% w/w CDHP may not be due to specific        acetate buffer concentration on lysozyme solubility. Jour
interaction with the protein, but rather maintenance of the       nal of Crystal Growth, 6, 112-117.
protein in the very stable suspended crystalline form. Because      11. Fraser, K.J., Izgorodina, E.I., Forsyth, M., Scott, J. L., &
there appears to be a net loss of protein when sampling from       MacFarlane, D. R. (2007). Applications of ionic liquids in
the same vial after 2 months of storage, possibly due to  25    the chemical industry. Chem Commun, 3817-3819.
adhesion to the vial and/or chemical degradation, Storage     12. Fujita,  F., MacFarlane, D. R., & Forsyth, M. (2005).
beyond 2 months would not be recommended in 80 wt %       Protein solubilising and stabilizing ionic liquids. Chemical
CDHP Solution.                                            Communications, 4804-4806.
  Although results with cyt Chave suggested that high con      13. Fujita, K., Forsyth, M., MacFarlane, D. R., Reid, R. W., &
centrations of CDHP are needed to achieve increased protein 30     Elliott, a D. (2006). Unexpected improvement in stabilitystability, the present invention and data presented herein with                                                       and utility of cytochrome c by solution in biocompatible
HEWL formulated in aqueous solutions of CDHP up to 40%        ionic Liquids. Biotechnology and Bioengineering, 1209
w/w show that thermal stability can be enhanced at low       1213.
CDHP concentrations which is an unexpected result. When                                                                  35  14. Fujita, K., MacFarlane, D. R. Forsyth, M. Yoshizawasolutions of HEWL were formulated at 1 mg/ml in increasing                                                                          Fujita, M., Murata, K., Nakamura, N., et al. (2007). Soluconcentrations of CDHP and analyzed (without no dilution),                                                                            bility and stability of cytochrome c in hydrated ionic liqan exponential relationship between the thermal transition                                                                     uids: effect of oxo acid residues and kosmotropicity.midpoint temperature and CDHP concentration was seen.
Also, the enthalpy change of unfolding and the entropy       Biomacromolecules, 8, 2080-2086.
change of unfolding increased. The result was an increase in 40  15. Fujita, K., Nakamura, N., Igarashi, K., Sameima, M., &
the thermal stability of the protein and a preference for the      Ohno, H. (2009). Biocatalytic oxidation of cellobiose in an
folded state as the concentration of CDHP is increased, pos       hydrated ionic liquid. Green Chemistry, 11 (3), 351-354.
sibly due to kosmotropic effects. The stabilizing effect was      16. Hedoux, A., Willart, J. F., Ionov, R., Affouard, F., Guinet,
prominent as low as 20% w/w CDHP (1.243 M). Although the        Y., Paccou, L., et al. (2006). Analysis of Sugar Bioprotec
osmolality of such a formulation is somewhat high for direct 45    tive  Mechanisms  on  the  Thermal  Denaturation  of
injection, this formulation could be useful in an osmotic      Lysozyme from Raman Scattering and Differential Scan
pump or other delivery device vehicle Such as nanoparticles.       ning calorimetry Investigations. Journal of Physical Chem
Many therapeutic proteins maintain Suitable functional and         istry, 110 (45), 22886-22893.
structural integrity for only a few hours in liquid formulation.      17. Hirano, A., Hamada, H., Okubo, T., Noguchi, T., Higashi
Even a Small increase in protein stability could have a large  50    bata, H., & Shiraki, K. (2007, September). Correlation
economic impact as well as Substantially better patient out      between thermal aggregation and Stability of lysozyme
COCS.                                                      with salts described by molar Surface tension increment: an
                                                                 exceptional propensity of ammonium salts as aggregation
              REFERENCES                              suppressor. The Protein Journal, 423-433.
                                                                  55                                                                        18. Jiang, G.W. (2002). Assessment of protein release kinet
1. Abbott, A., & Davies, D. (2005). Salty Solvents—Ionic         ics, stability and protein polymer interaction of lysozyme
   Really. Royal Society of Chemistry.                           encapsulated poly(d.1-lactide-co-glycolide) microspheres.
2. Ansari, A., Jones, C. M., Henry, E. R. Hofrichter, J., &       Journal of Controlled Release, 137-145.
   Eaton, W. A. (1992). The role of solvent viscosity in the      19. Kolarama Information. (2006). The protein therapeutics
  dynamics of protein conformational changes. Science, 256  60    market: the science and business of a growing sector. New
   (5065), 1796-1798.                                     York City, N.Y.: Kolarama Information.
3. Baker, S. N., & McCleskey, M. T. (2004). Fluorescence     20. Kragl, U., Eckstein, M., & Kaftzik, N. (2002). Enzyme
   studies of protein thermostability in ionic liquids. Chem        catalysis in ionic liquids. Current Opinion in Biotachnol
  Comm, 8, 940-941.                                            ogy, 13 (6), 565-571.
4. Branchu, S. (1999). A central composite design to investi  65  21. Krasnyuk Jr., I. I. (2009). Effects of solid dispersions on
   gate the thermal stabilization of lysozyme. Pharmaceutical       the solubility of antibiotics. Pharmaceutical Chemistry
  Research, 702-708.                                              Journal, 43 (4), 226-229.

---

## Page 35

US 9,289,381 B2
                 35                                      36
22. MacNally, E. J., & Park, J. Y. (1990). Encyclopedia of                       Example 3
  Pharmaceutical Technology 2" edition (Vol. 3). (J. Swar
   brick, & J. C. Boylan, Eds.) NY, N.Y.C: Informa Health         Cyto-Toxicity and Biocompatibility of a Family of
  Care.                                                         Choline Phosphate Ionic Liquids Designed for
23. Mathews, C. K. van Holde, K.E., & Ahern, K.G. (2000).                   Pharmaceutical Applications
  Biochemistry (3rd. ed.). San Francisco, Calif.: Addison
  Wesley Longman, Inc.                         CDHP was demonstrated to improve the thermostability                                                      and shelflife of several model proteins, thus exhibiting poten24. Merck Chemicals. (2004, June). Chemistry with a future:                                                                                   tial as a stabilizing excipient or solvent for protein therapeu  white         gold. (M. KGaA, Editor) Rtrvd 6/07 from www.  10  tics. Before novel compounds and ionic liquids (Ils) can be  merk.de/servlet/PB/show/1359290/                                                        used for biomedical applications, comprehensive data  is  IL%20white%20gold.pdf                                                              required to establish biocompatibility, including cytotoxicity25. Micaelo, N. M., & Soares, C.M. (2008). Proteinstructure                                                                      effects and solution behavior. In this study, five phosphate  and dynamics in ionic liquids: insights from molecular                                                         based anion moieties were analyzed: HPO,(DHP), dibutyl  dynamics simulation studies, Journal of Physical Chemis  15 phosphate (DBP), bis(2-ethylhexyl) phosphate (BEH), bis(2.
   try, 112, 2566-2572.                                          4,4-trimethylpentyl) phosphinate (TMP), and O,O'-diethyl
26. Millero, F. J. Ward, G. K.,& Chemirkin, P. (1976), Partial     dithiophosphate (DEP), all paired with the cation choline (C).
   specific Volume, expansibility, compressibility, and heat     Toxicity levels for these compounds and IIs and common
  capacity of aqueous lysozyme solutions. The Journal of     Sugars and salts, were established using a J774 murine mac
   Biological Chemistry, 251 (4), 4001-4004.                 rophage cell line. The Sugar trehalose, and the simple salts
27. Parrow, M. W., Burkholder, J. M., Deamer, N.J., &    sodium chloride and choline chloride yielded ECs  values of
  Ramsdell, J. S. (2005). Contaminantfree cultivation of Pfi    >100, 63 and 34 mM, respecift vely. The ECso values (mM) of
   esteria Shumwayae (dinophyceae) on a fish line. Aquatic   CDHP (20), choline dibutyl phosphate (CDBP) (9.1), and
  Microbial Ecology, 39, 97-105.                              choline O,O'-diethyl dithiophosphate (CDEP) (8.2) were
28. Powroznik, B. (2004). Enhancement of lysozyme stabil  25 lower than, but within the range of simple salts NaCl (62.8)
   ity and activity by polyamines. Biochimie, 651-656.         and choline C1 (33.7). The ECs  values of CTMP and CBEH
29. Robinson, G. W., & Cho, C. H. (1999). Role of hydration    were considerably lower, 0.25 and 0.3 mM, respectively.                                       CDHP and CBEH displayed a 4ollicle response. Osmolality  water in protein folding. Biophysical Journal, 77, 3311
   33.18.                                                measurements indicated  that CDHP, CDBP, and CDEP
                                                                30  exhibit nearly complete dissociation in aqueous solution,30. Shiu.Y.-J., Jeng, U.-S., Huang, Y.-S. Lai, Y.-H. Lu, H.-F.                                                          with osmotic coefficients of 1.0, 0.9, and 0.8, whereas CTMP  Liang, C.-T. et al. (2008, Jul. 15). Global and local struc    and CBEH have coefficients of 0.5 and 0.3 and are more   tural changes of cytochrome c and lysozyme characterized                                                          molecular in character. A high correlation between the ECso  by a multi-group unfolding process. (T. B. Society, Ed.)                                                             value and the anion mass fraction indicated that anion size
  Biophysical Journal, 4828–4836.                            35 and the presence of moderately long and/or branched alkyl31. Singh, S., & Singh, J. (2003). Effect of Polyols on the                                                              chains may affect viability.  Conformational Stability and Biological Activity of a                                        CDHP has been shown to dramatically improve the shelf
  Model Protein Lysozyme. AAPS PharmSciTech, 101-109.      life of cytochrome c when used as the major co-solvent with
32. Stevenson, C. L. (2000). Charactorization of protein and     water, and in Solution the protein was shown to retain both
  peptide stability and solubility in non-aqueous solvents.  40  structure and activity.   The ability of proteins to retain a
  Current Pharmaceutical Biotechnology, 1, 165-182.           properly folded structure is paramount to their function in
33. Sugar, D. (1952). Measurement of lysozyme activity and     Vivo and efficacy in therapeutic application. The potential
  the ultraviolet deactivation of lysozyme. Biochim Biophys     benefit of affording storage and delivery in a liquid vehicle
  Acta, 8,302.                                       makes formulation in CDHP an alternative to costlier lyo
                                                               45  philized products. The aim of this study was to evaluate the34. Ugwu, S.O., & Apte, S. P. (2004, Mar. 1). The effect of
  buffers on protein conformational stability. Pharmaceuti     cytotoxicity of a panel of choline based solutions and ILS in
   cal Technology, 86-113.                                    order to identify the least toxic for continued development as
35. Uversky, V. N., & Permyakov, E. A. (2007). Methods in     potential components in pharmaceutical formulations. Ionic
   proteinstructure and stability analysis: conformational sta     liquids studied involve choline as a cation and a series of
   bility, size, shape and Surface of protein molecules. Haup  50 phosphate and phosphinate anions to investigate the possible
  pauge, N.Y.: Nova Publishers.                                  roles of structural modifications, compared to choline dihy
36. Wade, L. (2003). Organic chemistry. Upper City River,    drogen phosphate itself, in the cytotoxicity of this family of
   N.J.: Prentice Hall. Wetlaufer, D. (1973). Nucleation, rapid    compounds. The choline  salts of  dihydrogen phosphate
   folding, and globular interchain regions in protins. Pro    (DHP), dibutyl phosphate (DBP), bis(2-ethylhexyl) phos
  ceedings of the National Academy of Sciences of the  55  phate   (BEH),   bis(2,4,4-trimethylpentyl)   phosphinate
  United States of America, 70 (3), 697-701.                (TMP), and O,O'-diethyl dithiophosphate (DEP) were inves
37. White, E.T., Tan, W. H., Ang, J. M., Tait, S., & Litster, J.     tigated. Simple salts and Sugars were included for compari
  D. (2007). The density of a protein crystal. Powder Tech    SO.
   nology, 179 (1-2), 55-58.                                  Another important consideration in the development of ILs
38.  Worthington  Biochemical  Coorporation.  Lysozyme.  60  for biological formulation is that the osmotic strength of IL
  Retrieved Aug.  1, 2008, from www.worthington-bio     containing solutions must be well-defined. Recent work has
  chem.com/LY/default.html                            shown that many of the ionic liquids that are of interest in
39. Yoshizawa-Fujita, M., Fujita, K., MacFarlane, D. R., &     bio-applications are not fully ionic; instead they exist as ion
   Forsyth, M. (2007). A new class of proton-conducting     pairs in the neat liquid. This observation indicates that an
   ionic plastic crystals based on organic cations and dihydro  65  intermediate level of dissociation is occurring for these ILs
  gen phosphate. (E. B. V., Ed.) Electrochemistry Commu    where the solution behavior is between that of a fully ionic
   nications, 9, 1202-1205.                                        liquid and a molecular solvent Such as water. Since the osmo

---

## Page 36

US 9,289,381 B2
                 37                                      38
lality of the IL could potentially be much lower than one     effects as compared to the four-carbon side chains on CDBP
would expect for a simple salt, we have acquired osmolality     (FIGS. 18 and 19); however, these two compounds were
measurements using a vapor pressure osmometer for the cur     approximately twofold more toxic than CDHP (Table 6).
rently investigated family of choline salts.                    The compounds CTMP and CBEH gave ECso values of
   Results and Discussion.                                  <0.25 and 0.30 mM, respectively, lower than all the other
  The structures of the phosphate based solutions including    compounds tested (Table 6). Media based solutions prepared
ILs included in this study are shown in FIG. 18. To establish    with CTMP appeared to form emulsions or micellar solutions
the relative toxicity of these compounds, mouse macrophage     that may have trapped, or even precipitated media nutrients.
cells (J774) were used as a model cell type. The J774 mac    Due to these low solubility and solution characteristics, the
rophage cell line was chosen due to proven applicability in  10 ECso value for CTMP can only be estimated, and is assumed
particulate toxicity and intracellular drug effectiveness stud     to be lower than 0.25 mM (FIG.20). Since the ECs of choline
ies.' ' Cell viability following exposure to ILS was mea     chloride did not display toxicity at the lower concentration
Sured using a resaZurin-based fluorometric assay to estimate     level where the CTMP and CBEHECs values occur, it can be
the number of metabolically active cells in 96-well plates.     concluded that there is not an intrinsic cation effect on cyto
Viable cells reduce resaZurin to fluorescent resorufin whereas  15  toxicity. Thus, the toxicity of CTMP and CBEH can be attrib
nonviable cells do not generate a significant fluorescent sig     uted to the anion and in the case of CTMP and CBEH, the
nal.                                                         longer and branched alkyl chain Substituents.
  Stock Solutions of ionic liquids were prepared in culture       In the case of both CDHP and CBEH, cell viability
medium composed of Dulbecco's modification of Eagle's     increased with  increasing  concentration  before  passing
medium (DMEM) with L-glutamine, 4.5 g/L glucose and    through a maximum and eventually falling away with addi
sodium pyruvate complemented with 10% fetal bovine serum     tional increasing ionic liquid concentration, i.e., both com
and 1% penicillin/streptomycin. Cells were exposed to 1:1    pounds induced a Subtoxic stimulus or hormetic response
serial dilutions of each IL compound in 96-well plates for 48     (FIG. 21). The inverted U-shaped dose response curves for
hours. Each plate contained a media and an untreated cells    both data sets were fit with a dose-response model (Statistical
                                                                  25  analyses, Equation 1) and a modified logistic model thatcontrol. Concentrations ranged from 0.2 to 113 mM, and were
optimized  for  complete  concentration-response  curves     includes a parameter that describes hormesis  (Statistical
including hormetic effects.                                      analyses, Equation 2). The ECso values obtained from the two
  The simple sugar (trehalose) showed incomplete inhibition    models were within error of one another, and the hormetic
in the concentration range tested and is reported with an    model appears to describe the toxicity behavior of CBEH
                                                                30ECs >100 mM, while the simple salts (sodium chloride, and     reasonably well. However, the hormetic effect of CDHP
choline chloride) had ECso values of 63 and 34 mM respec    showed considerable variability. The significant changes in
tively (Table 6).                                               the character of the hormetic trend for CDHP, especially the
                      TABLE 6
           List of compounds, MWs, mol fractions, Log EC50s, and osmotic coefficients.
                                                        Log ECso
                                 Anion     Log ECso, IM    M       Osmotic
Compound           MW,            3.SS      (Dose Response    (Logistic   Coef, p in
(abbreviation)             g/mol    fraction, X       Model)       Model)   HO
Choline chloride (ChCI)    139.625        O.3          4.53 (4)       na         O.86
Sodium chloride (NaCl)     58.443     O6            4.8 (1)       na          O.91
Trehalose (Tre)            378.33     na               5.1 (5)       na          1.01
Choline dihydrogen      201158        O.S           4.31 (4)        4.28 (6)       O.98
phosphate (CDHP)
Choline dibutyl           313.366        0.7          3.96 (3)       na         O.90
phosphate (CDBP)
Choline bis(2,ethyl        425.574       O.8          2.47 (3)        2.43 (3)       O.31
hexyl) phosphate
(CBEH)
Choline bis(2,4,4-         393.574       0.7          2.39 (2)       na
trimethylpentyl)
phosphinate (CTMP)
Choline O,O'-diethyl      289.382     O6           3.91 (2)       na         O.76
dithiophosphate (CDEP)

 Anion mass fraction, x = mi?m, where m; = mass of anion, m = total mass of substance in system.
 Dose response model as defined in equation 1, Error of last digit in LogEC50 value denoted in parentheses,
 Modified dose response model as defined in equation 2. Error of last digit in Log EC50 value denoted in parentheses.
 Osmotic coefficient () = (osmol/L);nx C, where n = number of particles, C = molar concentration of solute, osmol/L
= osmolarity, Measured for 100 mM solutions prepared in deionized water,
                                                                  60
The ECs  values (mM) of CDHP (20), CDBP (9.1), and    range of hormesis, were not accommodated well by the cur
CDEP (8.2) listed in Table 6 were lower than simple salts,     rent model indicating the need for improved hormesis model
Suggesting that they were slightly more toxic, but still within    development, which will be addressed further elsewhere.
the range of typical physiologic salts as shown in FIG. 19. The        In addition, CDHP was observed to exceed the buffer
ECso  value for CDHP  is consistent with toxicity trends  65  capacity of the complemented media at high concentrations
observed previously (Table 6).' The short sulfanyl and sul    (>50 mM) as indicated by a color change in the pH indicator.
fanylidene groups on CDEP appear to yield similar toxicity    At 100 and 50 mMCDHP, the pH was 6.48 and 6.77 (+0.01)

---

## Page 37

US 9,289,381 B2
                 39                                      40
respectively. After dilution with media to 25 mM, the solution     Sufficient Substrate solution and enzyme activity condi
had a pH of 7.52, close to that of the media alone. This      tions.'    ' To determine if a similar anion size effect for
concentration  is higher than the ECso  value for CDHP.     toxicity could be occurring, the ECso/mM value was com
Although during the cell based assay Subtle changes in pH     pared to both the osmotic coefficient and an approximate
near the ECso value cannot be ruled out, it is not clearly    measure of anion size for this series of choline based ILs
apparent whether toxicity can be attributed to pH effects                                                            (FIG.22). The anion size is inferred from the calculated masswhere  viability  decreases  as  the  buffer  capacity   is                                                                   fraction of anion in the ionic liquid. Since the cation is comapproached.                                            mon to all the salts studied and assuming that their densities  Choline is an essential nutrient, and serves many physi                                                                are approximately the same, the mass fraction anion  is aological roles due to its incorporation in membrane compo  10                                                                     reflection of anion size. Looking at the ECso values versus thenents, signaling molecules, and neurotransmitters."   It is                                                          osmotic coefficients for the choline salts, it appears that therereported that choline does not permeate cell membranes, but
must be transported by a carrier-mediated system."  Inverted      is clustering of the more toxic and molecular-like salts (FIG.                                                         22A). Comparison of ECso to the anion-mass-fraction showsU-shaped dose-response curves have been reported for cho                                                                   that apparent anion size and toxicity are closely correlatedline in cholinergic drug studies, and for high-affinity choline  15
transporters.'   '  Brock suggests that the biphasic effect of    (FIG.  22B),  with  a  correlation  coefficient  of  (Adj.                                                          R-Square-0.98, OriginPro. 8). The trend observed for ECs/the dose-response curves indicates that more than one intracellular process is involved." Biphasic dose-responsecurves  mM versus anion mass fraction suggests that higher anion                                                     mass fractions correlate with higher J774 toxicity (FIG.22B).indicate complex physiological action, and gave rise to the                                                           This indicates that changes in anion size due to the incorpoconcept of hormesis described as low-dose stimulation fol                                                                  ration of moderately long and or branched alkyl chains, orlowed by high-dose inhibition.'    '    '  The fact that theseeffects were not observed with choline chloride or with the     substitution with sulfur groups may affect viability such as                                                                   that seen for ILS CTMP, CBEH, and CDEP. The reason forother choline-based ionic liquids included in this study raises                                                                        this correlation is not clear, but could be related to interactionsan interesting question with respect to what exactly is occur                                                                  25 with lipid membranes, or possible electronic effects due to thering that manifests as the hormetic effect.                                                                 differences in charge distribution of potential ion pairs within  To improve the biocompatibility of injected therapeutics                                                              the solvent.the osmolality of such solutions are ideally formulated to benear that of extra- and intracellular fluids. Otherwise the      The anion effect was also examined through comparison of                                                              the ratio of the ECso values of the chloride containing cholineimbalance in the chemical potential of water inside and out                                                                30  reference salt and the ECso for each of the choline based ILside the cells near the injection site will result in a rapid                                                   compounds tested. The anion effect ratio (AR) (Equation 3)transport of water to/from the cells. This can cause cell injury,                                                  was first used by Stoke to classify the toxicity of anions inresulting in pain at the injection site. Because ionic liquids                                                                  ionic liquids, where AR values <5 were considered noncan exhibit solution behavior ranging from molecular in                                                                cytotoxic or marginally  cytotoxic, and values >5 werenature to that of a fully dissociated ionic Solution, it is impor                                                                  35  described as significantly influencing cytotoxicity,tant to understand this behavior in order to predict final solu
tion osmolalities in formulations.’    ” Osmolality measure
ments of ILS formulated at 100 mM in water were determined
                                                                    AR   ECso (CCI)                                (3)using a vapor pressure osmometer. From these measure                                                                          T ECso (CY)ments, osmotic coefficients (cp) in water, which account for
the degree of non-ideality of a solution, were calculated so 40
that the degree of dissociation of each ionic liquid could be    where CC1 stands for choline chloride and CY stands for
assessed. CDHP, CDBP, and CDEP have osmotic coefficients     choline paired with anion, Y. CDHP has the lowest cytotox
of cp=1.0, 0.9, and 0.8 respectively at 100 mM (Table 6), where      icity with AR=1.7, followed by CDBP=3.7. The CDEP
a value of 1 indicates 100% dissociation. CTMP (cp=0.5) and    AR=4.1 is approaching a borderline value of 5 and could be
                                                                45  considered marginally cytotoxic. The AR values for CTMPCBEH (p=0.3) have very low coefficients (Table 6), and
although these ionic liquids are composed of ionic salts, it     (137) and CBEH (113) are over an order of magnitude greater
appears that they may have not dissociated completely. While     than 5, and so these two anions (TMP and BEH) are consid
electrostatic effects can also cause depression in osmotic     ered to significantly influence the toxicity of these two ionic
coefficients, osmotic coefficients at or below 0.5 for CTMP     liquids, and therefore are not ideal for further exploration as
and CBEH seem to indicate more molecular versus ionic  50  excipients for pharmaceutical application. While the actual
Solution character.                                  mode of CTMP and CBEH anion toxicity has yet to be deter
  Although the other compounds were completely miscible    mined, it appears to be consistent with toxic effects observed
with water and complemented media at all concentrations     for cations with longer alkyl chains.'  'Longer alkyl chains
investigated, CTMP formulated at 10 and 100 mM appeared     impart the anion with a hydrophobic tail that is lipophilic, and
to precipitate at 4°C., and form an emulsion or dispersion at  55  in an effort to escape contact with the aqueous environment it
25°C. and 37°C. The 1 mM CTMP used as the Stock Solution     will associate and possible intercalate with cell membranes.
for the cell based assays did not exhibit the same insolubility       Still, the molecular nature of the ion pairs suggested by their
profile i.e., CTMP appears to be miscible with water at 1 mM    osmotic coefficients may impart a mixed cytotoxicity in that
concentrations. Still, the characteristics of the CTMP emul    an uncharged species introduced to the membrane may
sions remain to be elucidated since potential particle forma  60 enable membrane interactions and increase cytotoxicity.’
tion in the solutions containing higher levels of CTMP might       Materials.
involve nutrient sequestration which would adversely affect      Sodium chloride was purchased from VWR International,
cell viability in addition to lowering the osmolality.              C.-O-trehalose dehydrate was purchased from Ferro Pfan
    It has been shown for a series of acetate based ILs that      Stiehl Laboratories. Choline chloride, choline hydroxide,
                                                                    65  methanol, dihydrogen phosphate, dibutyl phosphate, bis(2-higher anion molar concentrations enhanced the dissolution
of substrates in the pure IL, but lowered enzyme activity     ethylhexyl) phosphate, and O,O'-diethyl dithiophosphate
indicating that an optimum ion size is required to satisfy both    were obtained from Sigma-Aldrich. Bis(2,4,4-trimethylpen

---

## Page 38

US 9,289,381 B2
                  41                                       42
tyl) phosphinate was obtained from Cytec. All chemicals      cells were incubated for up to one week in order to obtain a
were used as received, except as otherwise specified. ELGA     population between 1x10  and 1x10° cells/mL. The cells
Purelab Ultra water (18.2M cm) was used in the preparation    were scraped, centrifuged, and transferred to 20 mL spinner
of all water based solutions.                                       flasks where they were maintained at a density less than
   Ionic Liquids.                                       1x10 cells/mL. Under these culture conditions, the genera  Choline dihydrogen phosphate (CDHP) was synthesized at     tion time of the cell line was about 24 h.
Monash University according to previous methods.  Cho                                                              ResaZurin Metabolism Assay.line salts of dibutyl phosphate (CDBP), bis(2-ethylhexyl)                                                               All assays were conducted in 96-well Costar cell culturephosphate (CBEH), bis(2,4,4-trimethylpentyl) phosphinate                                                                   plates (Fisher) at 37°C. The viability of J774 cells exposed to(CTMP), and O,O'-diethyl dithiophosphate (CDEP) were  10                                                                  ionic liquids was measured using a fluorometric assay basedsynthesized at Monash University as described below. Cho                                                   on the reduction of resaZurin (Sigma-Aldrich).24 ResaZurinline dibutyl phosphate (CDBP) was synthesized via a neutralization reaction as shown in Scheme 2.                    was prepared as a stock solution of 0.437 mM in phosphate                                                              buffered saline (PBS, 1x) without calcium and magnesium
                                                                       15  (Cellgro, Mediatech), and was stored in the dark at 4°C. The                                                              stock resaZurin solution was diluted to 0.0437 mM in DMEM
Scheme 2: Synthesis of CDBP via a neutralization reaction.                  containing 10% FBS and 1% P/S (full complement media).
     O                                                  Stock solutions of ionic liquids (ILS) (1-100 mM) were pre
                                        --                                                           pared in full complement media. For comparison of toxicity,(CHO)2POH  +  (CH3)N-CH2CH2OH OH ->                              O                      solutions of sodium chloride, choline chloride, and trehalose
                                          --                                 were included in the same concentration range. Each plate
             (CH3)N-CHCH-OH  OP(OCHo)   +  H2O     contained a negative (no-cells) control, a vehicle (untreated
                                                                       cells) control, and two IL dilution series with three replicates
                                                                each. Cells in full complement media were plated at a density A typical procedure for the synthesis of CDBP is as fol                                                      of 1x10" cells per well, and were incubated 2 hat 37° C. tolows: 3.342 g (0.0159 mol) dibutyl phosphate was dissolved 25                                                             allow attachment. After 2 h, the Supernatant was removed,in 4 g of ethanol, a choline hydroxide-methanol Solution                                                      and IL supplemented media was added. The cell viabilitycontaining 0.0159 mol of choline hydroxide was added drop                                                              assays were carried out using a 1:1 dilution series in the rangewise, and the mixture was stirred at room temperature for                                                      of 100 to 0.2 mM (CDHP, CDBP, and CDEP) or 1 to 0.002more than 4hrs; the solvent was removed by distillation, and                                                                30 mM (CTMP and CBEH). The cells were incubated for 48 h.the product was dried under vacuum at 70° C. for at least 2                                                             After 44 h, the IL supplemented media was removed, 0.0437days. The other three choline ILs were synthesized via the                               mM resaZurin was added, and the cells were incubated ansame procedure as that of CDBP, using bis(2-ethylhexyl)                                                                 additional 4 h. Assays were repeated in parallel on cellsphosphate instead of dibutyl phosphate for CBEH, using bis                                                            obtained from 3-5 different dates to allow for variability(2,4,4-trimethylpentyl) phosphinate for CTMP, and using                                                       between cultures. Cell viability was measured at      590O,O'-diethyl dithiophosphate for CDEP,                       35                                          nm (W-560 nm) in a Synergy HT multi-detection micro  The resultant salts were characterized using electrospray                                                                   plate reader (Bio-Tek Instruments).mass spectrometry and thermogravimetric analysis. Electro                                                                 Osmolality.spray mass spectroscopy (conet;35V), m/z (relative intensity,                                                                    In order to assess tonicity effects of the ILs, the osmolality%) for CDBP: ES", 103.9 (CHCHOHIN, 100), 417.4                                                             40 of IL solutions (100 mM) prepared in water was measured(M-CHICHOHIN', 10); ES, 153.0 (ICHOIOPO,                                                           using a VaproTM vapor pressure osmometer (Wescor). The7): 209.2 (CHOOPO, 100). CBEH: ES", 103.9 (ICH),                                                    osmometer was calibrated against a set of 290, 1000, and 100(CHOHIN',  100); ES, 321.3 (ICHOIOPO,  100).                                                   mmol/kg osmometry standards prior to each sample.CTMP: ES", 103.9 (CHCHOHIN, 100), 497.5 (M-                                                                            Statistical Analyses.CHCHOHIN, 7); ES, 289.4 (ICHOPO, 100),                                                                45   Background fluorescence was determined on wells con579.4 (ICHOPOH-CHOPO, 10). CDEP: ES",                                                                 taining resaZurin but no cells (negative control), and this value103.8 (CHCHOHIN,  100); ES,  156.8 (ICHO    was subtracted from all control and treated wells. Nonlinear
SPS, 18), 1848 (ICHOISPS, 100).                                                                regression was used to fit the relationship between cell viabil A PerkinElmer Thermogravimetric Analyzer (TGA) was                                                                           ity (fluorescence) and the decadic logarithm of the testedused to test thermal stability of the choline ILs. Scan rate was                                                                 concentrations. The general equation for a sigmoidal dose10.0° C./min from room temperature to 800° C. under a  50                                                            response with variable slope (four-parameter logistic equanitrogen atmosphere. See FIG. 23 for thermal traces.                                                                    tion) was used to generate LogECso values for each com  Alkyl chain length and Substituent composition were                                                    pound (OriginPro 8.4) (Equation 1)altered for the anions to test the influence of variation in the
anion. The chemical structures of the compounds are given in
FIG. 18.                                                         55                                                                                                   (A2 - A1)   Cell Line.                                                                       y = A1 +                                             (1)                                                                                                                                        1   10(logo-x)P
  Mouse macrophage cells (J774.A. 1) were obtained from
American Type Culture Collection (ATCC. Number TIB
67TM), Manassas, Va. Cultures of J774A.1 were grown at 37°    where X is the concentration of the substance to which the
C. in a humidified atmosphere in a total volume of 10 mL of 60  cells are exposed, y is the physiological response normalized
Dulbecco's modification of Eagle's medium (DMEM, with     for the interval from 1 to 0, A2 is the maximum y value at the
phenol red) with L-glutamine, 4.5 g/L glucose and sodium     top plateau (1,x=0), A1 is the minimum y value at the bottom
pyruvate (Mediatech, 10-013-CM) supplemented with 10%     plateau (O). Logo (Log ECs) is the X value when the
fetal bovine serum (FBS) (Atlanta Biologicals, S11150), 1%     response is halfway between the minimum and the maximum.
5000 IU penicillin 5000 ug/mL streptomycin (P/S) solution  65 The p value (HillSlope) or slope factor describes the steep
(Mediatech, 30-001-CI), pH 7.53+0.01 under 5% CO, in 250     ness of the curve and is negative, i.e., the curve decrease as X
mL CellstarR tissue culture flasks (Greiner bio-one). The     increases (inhibitory response to growth).

---

## Page 39

US 9,289,381 B2
                  43                                      44
   In the case of compounds CDHP and CBEH, cell viability      8. K. Fujita, M. Forsyth, D. R. MacFarlane, R. W. Reid and G.
appeared to  increase with increasing concentration  until       D. Elliott, Biotechnology and bioengineering, 2006, 94.
being reduced with increasing concentration, i.e., these com       1209-1213.
pounds induced a subtoxic stimulus or hormetic effect. The      9. K. J. Fraser, E. I. IZgorodina, M. Forsyth, J. L. Scott and D.
concentration-response curves were  fit with both a dose       R. MacFarlane, Chemical communications (Cambridge,
response (four-parameter logistic) model and a modification       England), 2007, 3817-3819.
of the four-parameter logistic model (Equation 2),               10. D. M. Brown, K. Donaldson and V. Stone, Respiratory
                                                                    research, 2004, 5, 1-12.
                                                                    11. E. L. Wright, D. C. Quenelle, W. J. Suling and W. W.
                                                              2   10    Barrow, Antimicrobial agents and chemotherapy, 1996, 40,              y = A1                                                     (2)
                                                            22O6-2208.
                                                                        12. R. M. Vrikkis, K. J. Fraser, K. Fujita, D. R. Macfarlane
                                                       and G. D. Elliott, Journal of biomechanical engineering,
                                                                       15    2009, 131,074514.
                                                      13.M. Brock, A. C. Nickel, B. Madziar, J. K. Blusztajn and B.wherefclescribes the hormetic effect and a governs the rate of                                                                Berse, Brain research, 2007, 1145, 1-10.
hormetic manifestation. A1 and                                     14. J. F. Flood, D.W. Landry and M. E. Jarvik, Brain research,
A2 carry the same meaning as in Eqn, 1, however p no longer       1981, 215, 177-185.
accurately describes the Hill Slope, and X  provides a lower      15. E. J. Calabrese and L. A. Baldwin, Trends in pharmaco
bound on the ECso level. The Log ECso values derived from        logical sciences, 2002, 23, 331-337.
each model are within overlapping confidence intervals. The      16. E. J. Calabrese and L. A. Baldwin, Critical reviews in
ability of the modified-four-parameter logistic model to       toxicology, 2001, 31, 353-424.
describe the hormetic responses and the level of hormesis for      17. G. D. Elliott, R. Kemp and D. R. MacFarlane, in Ionic
CDHP and CBEH are the subject of a separate body of work.  25    Liquids: Industrial Applications for Green Chemistry, eds.
  Conclusion.                                             N. Plechkova, K. Seddon and R. Rogers, ACS, 2009, pp.
  This family of choline phosphate salts exhibit a range of       1-13.
toxicities from low (CDHP) and within the range of basic      18. H. Zhao, G. A. Baker, Z. Song, O. Olubajo, T. Crittle and
physiologic salts, to high (CTMP and CBEH) based on the      D. Peters, Green Chemistry, 2008, 10,696-705.
anion effect ratio described by Stolte.  If a high IL concen  30  19. H. Zhao, C. L. Jones, G. A. Baker and J. V. Cowins, Green
tration is required to achieve a stabilization effect these ILs       Chemistry, 2009, 11, 1128-1138.
might be best implemented as co-formulation  stabilizers     20. S. Stolte, M. Matzke, J. Arning, A. Boschen, W.-R. Pitner,
within slow-release nano- and micro-particles to maximize      U. Welz-Biermann, B. Jastorff and J. Ranke, Green Chem
the biocompatibility. We have observed that the choice of                                                                  35     istry, 2007, 9, 1170-1179.
anion can greatly affect the osmotic coefficient of the Solu     21. R. A. Kumar, N. Papaiconomou, J. M. Lee, J. Salminen,
tion. For example CDHP dissociates completely at 100 mM,       D. S. Clark and J. M. Prausnitz, Environmental toxicology,
with an osmotic coefficient of 1.0, whereas CBEH has an       2009, 24, 388-395.
osmotic coefficient of 0.3, and would be considered to have     22. E. Fulladosa, J. C. Murat, J. C. Bollinger and I. Villaes
behavior more consistent with a molecular solvent. This 40    cusa, The Science of the total environment, 2007, 377,
would minimize the contribution to osmolality compared to       207-213.
traditional salts.                                                23. K. Fujita, D. R. MacFarlane and M. Forsyth, Chemical
                                                         communications (Cambridge, England), 2005, 4804-4806.
                                                                24. B. Page, M. Page and C. Noel, International Journal of
                                                                45    Oncology, 1993, 3, 473–476.
              REFERENCES                           25. N. Cedergreen, C. Ritz and J. C. Streibig, Environmental
                                                              toxicology and chemistry/SETAC, 2005, 24, 3166-3172.
1. J. P. Mann, A. McCluskey and R. Atkin, Green Chemistry,
  2009, 11,785-792.
2. N. Byrne and C. A. Angell, Journal of molecular biology,  50
  2008, 378, 707-714.                                                                       Example 43. K. Fujita, D. R. MacFarlane, M. Forsyth, M. Yoshizawa
   Fujita, K. Murata, N. Nakamura and H. Ohno, Biomacro                                                          High-dose  Interleukin-2  (IL-2)  is an FDA approved  molecules, 2007, 8, 2080-2086.                                                             therapy for the treatment of malignant melanoma and renal4. S. N. Baker, T. M. McCleskey, S. Pandey and G. A. Baker,  55
  Chemical communications (Cambridge, England), 2004,     cancers. IL-2 is administered systemically (i.v.) and leads to
  940-941.                                                    disease regression in 15-20% of stage IV metastatic mela
5. B. Jastorff, R. Stormann, J. Ranke, K. Molter, F. Stock, B.    noma patients. However, IL-2 is associated with grade 3 and
  Oberheitmann, W. Hoffmann, J. Hoffmann, M. Nuchter, B.    4 side effects and this significantly impacts its therapeutic
                                                                  60  use. The development of alternative administration strategies  Ondruschka and J. Filser, Green Chemistry, 2003, 5, 136
   142.                                                                         is limited by IL-2 instability in solution. In recent years a
6. S. Stolte, J. Arning, U. Bottin-Weber, M. Matzke, F. Stock,     family of low-melting point salts, termed ionic liquids, have
  K. Thiele, M. Uerdingen, U. Welz-Biermann, B. Jastorff    gained attention for their ability to increase protein stabiliza
  and J. Ranke, Green Chemistry, 2006, 8, 621-629.             tion in solution.
                                                                    657. M. Matzke, S. Stolte, K. Thiele, T. Juffernholz, J. Arning, J.      The aim of the current study was to determine if choline
  Ranke, U. Welz-Biermannd and B. Jastorff, Green Chem    dihydrogen phosphate (C-DHP) could function as a stabiliz
   istry, 2007, 9, 1198-1207.                                   ing excipient for IL-2 in liquid formulation.

---

## Page 40

US 9,289,381 B2
                 45                                      46
  Methods.                                                     Circular Dichroism.
  The effect of C-DHP on IL-2 thermal stability was mea       Far ultraviolet CD spectra were obtained on a JASCO
sured between 15° C. and 75° C. by circular dichroism at 222     J-715/J-720 spectropolarimeter calibrated with (1S)-(+)-10
nm. The cytotoxicity of increasing concentrations of C-DHP     camporSulfonic acid, ammonium salt. Spectra were obtained
                                                                      in 1.0 and 0.1 cm path length quartz cuvets depending onwas measured in mouse splenocytes and B16-F10 melanoma                                                              concentration of IL-2 in Solution. Spectra (five accumulationscells by trypan blue exclusion and resaZurin reduction assay.                                                                 for each sample) were acquired using a scanning speed of 10The biological activity of IL-2 and C-DHP-IL2 was deter                                                       nm/min, data pitch of 0.5 nm, response of 1 sec and bandmined by flow cytometry using HT-2 T cells, a cell line that                                                         width equal to 1.0 nm. Variable temperature scans were run atrequires IL-2 to survive and proliferate.                         10                                                        30°C./hour with a data pitch of 0.5°C., response of 1 sec and
   Results.                                               bandwidth of 1.0 nm while monitoring ellipticity at 222 nm.
  C-DHPat final culture medium concentrations of 1-30 mM     Variable temperature data was normalized such that the low
was not cytotoxic to splenocytes or B16-F10 melanoma cells     est and highest signals correspond to 0 and 1 respectively.
(FIG. 24). However at C-DHP concentrations of >35 mM,  15  Protein concentrations were determined on Stock solutions
C-DHP caused significant culture medium acidification and     prior to transfer to the cuvets and on aliquots taken from the
cell cytotoxicity, effects that were abrogated by the addition     cuvets after experimental runs were complete using a Bicin
                                                             choninic acid (BCA) protein assay kit (Pierce) with reconstiof sodium bicarbonate (FIG. 25). Under pH-buffered condi                                                                tuted IL-2 and bovine serum albumin (BSA) as standards.tions (final culture medium pH7.2-4), 30 mMC-DHP did not                                                                  Spectral deconvolution was done using the Dichrowebsignificantly modify the IL-2 melting (unfolding) tempera                                                              online server, http://dichroweb.cryst.bbk.ac.uk accessed onture (without C-DHP Tm=53.9° C.; with CDHP Tm=52.3°                                                         Nov. 10, 2010. Secondary structure analyses of IL-2 in theC.) or IL-2-dependant HT-2 cell proliferation. However,                                                          absence and presence of CDHP were determined by fitting
when HT-2 cells were stimulated to undergo proliferation    far-UV CD data using the published analysis algorithms
(FBS; 5% or 10% (v/v)), 30 mMC-DHP-IL-2 significantly  25 CDSSTR (reference set 4, 7 and SP175), CONTIN (reference
improved HT-2 cell viability as compared to cells treated with     set 4, 7 and SP175), SELCON 3 (reference set 4, 7 and
IL-2 alone (FIGS. 26 and 27).                                SP175), and K2d using the online server DICHROWEB
  Conclusions.                                              (Sreerama, 2000; Whitmore, 2004). The results from the dif
                                                                  ferent algorithms and databases were compared to assess  IL-2 is readily soluble in a C-DHPionic liquid, pH buffer  30                                                     which was the most appropriate method for IL-2 at the coning is required when C-DHPD-30 mM and, when used in a                                                                    ditions studied. The normalized root mean square standardbuffered solution, C-DHP significantly improves IL-2 activ                                                                deviation (NRMSD), and correspondence of the calculatedity in vitro.                                                      and experimental secondary structure were used to select the
                                                                  35  best deconvolution (Whitmore, 2004).
                                                               Results
                                                                 Circular Dichroism.                    Example 5                                                   The NRMSD values were above 0.1 using the CONTIN
                                                      and SELCON algorithms, the reported error was high for the
       Evidence for Choline Dihydrogen Phosphate         40 Kd2 algorithm for the highest concentration of CDHP used,      Enhanced Thermal Stability for Interleukin-2                                                      and the correlation between experimental and calculated
                                                                  spectra were poorer when using CONTIN, SELCON, or K2d
   Materials.                                                 algorithms (Whitmore, 2004). With NRMSD values all below
  Choline dihydrogen phosphate (CDHP) was prepared by     0.1, and excellent correspondence of the calculated and
the Monash group by standard methods (Fujita, 2005: Fujita,  45  experimental secondary structure, the CDSSTR algorithm
2007). CDHP has a melting temperature just over 100° C.     using reference sets 4, 7, and SP175 proved to be the best
and can be rendered liquid with the addition of a small amount    method for assessing secondary structure for IL-2. Out of the
of water.                                                        three databases used, reference set 7 yielded the lowest
   Solution Formulation.                       NRMSD values and the closest spectral fits, and the fit param
                                                                50  eters from this method are reported in Table 7. The reported  Lyophilized IL-2, human (GenScript) was reconstituted to                                                           secondary assignments from CDSSTR are  split into six1 mg/mL with sterile water and allowed to hydrate for 4 hours                                                                     classes: regular C-helix, distorted C-helix, regular B-sheet,at 4° C. prior to preparing working protein Solutions, All                                                                   distorted B-sheet, turns, and unordered (Sreerama, 2000). The
working protein solutions were allowed to equilibrate at 4°C.     regular and distorted C-helix, and B-sheet content have been
overnight before using. IL-2 Samples for CD measurements  55 combined for this report (Table 7).
were prepared at a concentration of 0.03 mg/mL for use in the       In the absence (30 mM NaHPO) or presence of 30 mM
1.0 cm cuvet and at 0.38 mg/mL for use in the 0.1 cm cuvet by    CDHP, the O.-helix and turn content of IL-2 were found to be
combining appropriate Volumes of (1) reconstituted 1 mg/mL     comparable, and a slight increase off-sheet with decrease in
IL-2 with (2) a stock solution of CDHP at pH 7.40 or (3)    unordered content seen in the presence of 30 mM CDHP
NaH2PO solution at pH 7.40. The final concentration of salts  60  (Table 7). As the CDHP content was increased to 185 mM, the
in the test solutions were (1) 30 mM NaH2PO, (2) 30 mM     B-sheet content stabilized, and C.-helix content increased with
CDHP, (3) 185 mM CDHP, or (4) 680 mM CDHP. For com     a further decrease in unordered content (Table 7). With 680
parison, 680 mM CDHP is ~12% (w/w). These solutions are   mMCDHP, the C-helix content increased more, with turn and
distinctly  different from  the  choline  “buffer   solutions  65 unordered content decreasing further (Table 7). A represen
recently described which exhibit a buffering action around     tative graph of the experimental spectra Superimposed with
pH 7.2 (MacFarlane, 2010).                                    the calculated spectra is shown in FIG. 28A.

---

## Page 41

US 9,289,381 B2
                 47                                      48
                       TABLE 7
             Secondary structure analyses of IL-2 in the absence and presence of CDHP
                    Secondary Structure Content                    Rescan, % Change

             30 mM    30 mM    185 mM   680 nM    30 mM   30 mM  185 mM 680 mM
           NaH2PO,   CDHP    CDHP   CDHP   NaH2PO,  CDHP  CDHP  CDHP
  C-Helix      O.40      O42        O.47        O.S3       -40      -43     -66     -68
  B-Sheet      O.13        O.18        O.19       O.17        S4         11      32      24
   Turns       O.17       O.17        O.17        O.13          6         6       18      38
 Unordered     O.30        O.23        O.19      O16        23       70      116      181
 NRMSD     O.O16      O.018      O.O13      O.OO2
   T.  C.    617        60.2        63.0        74.25
ICD spectra were measure at 25°C, prior to running variable temperature profile. All IL-2 solutions were at pH 7.40. Low
point analyzed was 190 mm for each set. The secondary structure contents were determined as outlined in Materials and
Methods using the CDSSTR algorithm and reference set 7.
'sample rescanned from 260 to 178 mm after cooling and thermastatting at 25°C. for 15 minutes. Percent change was then
calculated for before and after temperature scanning to estimate loss in ordered secondary structure as an assessment of
reversibility,
 Melting temperature (Tm) calculated by taking the first derivative of the temperature scan. The error in the reported values
is less than 3.3%.
 n = 3.
 n = 2.

  The melting temperature (T) of IL-2 was measured at 222       IL-2 contains one disulfide bond, and the possible presence
nm in 30 mMNaHPO, 30 mMCDHP, 185 mMCDHP, and    of reduced IL-2 in these solutions has not been ruled out
680mMCDHPallat pH 7.40. At the end of the initial thermal     (Brandhuber, 1987). Previously, it was observed that the far
                                                                  25Scan, the samples were allowed to cool and were thermostated   UV CD spectra of the native and reduced forms of IL-2 show
15 minutes at 25°C. before rescanning to assess reversibility     that both forms have ordered structures compared to IL-2
of the unfolding reaction. The normalized CD thermal dena     denatured in guanidine HCl, although the reduced form doesturation  scans appear  to  indicate cooperative  transition                                                       have less C.-helix content than native IL-2 (Yamada, 1987).behavior (FIG.28B). The protein at 85°C. still had significant                                                       However, near-UV CD revealed  that  the reduced formCD  signal  (data  not shown)  indicating  that thermally  30                                                            appears to not have a rigid tertiary structure and is quiteunfolded IL-2 retains some secondary structure. The high                                                                  similar to IL-2 denatured in the presence of guanidine HCltension voltage (data not shown) reveals an increased absor                                                       (Yamada, 1987). Further investigation into the influence ofbance upon melting indicating that unfolded IL-2 aggregates                                                              the thiol-disulfide couple on IL-2 stability in the presence ofsufficiently to scatter light. The IL-2 solutions made with 185                                               CDHP, or additives intended to reduce aggregation remain toand 680 mM CDHP contained macroscopically observable  35
precipitates upon removal from the instrument. Spectral res    be carried out. Still the increases observed in IL-2 ordered                                                                    structure as the concentration of CDHP is increased do tendcans confirmed the losses of C-helix content with increases in
                                                             Support positive effects on conformational stability and asunordered content and B-sheet structure (Table 7). The T  for                                                          such shows that CDHP holds promise as a stabilizing excipiIL-2 in 30 mMNaH2PO was 61.7°C. (Table 1). The T was
                                                             40  ent.slightly changed in the presence of 30 mMCDHP (T-60.2°
C.) or 185 mM CDHP (T=63.0°C.) (Table 7). However, at
680 mMCDHP-12.3% (w/w), the T  increased up to 74.2°                 REFERENCES
C., an increase of 12.5°C. indicating an increased structural
stability and resistance towards thermal unfolding (FIG. 28B,     T. Arakawa, J. S. Philo, Y. Kita, Kinetic and thermodynamic
                                                                45    analysis of thermal unfolding of recombinant erythropoiTable 7). These values compare well to those determined
calorimetrically where the T was 66°C. for 1 mg/mL IL-2 in         etin, Biosci. Biotechnol. Biochem. 2001, 65(6), 1321-1327.
20 mM sodium phosphate, 150 mM NaCl, pH 7.5 (Wang,      S. Branchu, R. T. Forbes, P. York, H. Nyqvist, A central
2008),                                                     composite design to investigate the thermal stabilization of
Discussion                                                  lysozyme, Pharm. Res. 1999, 16(5), 702-708.
  The investigation of the temperature dependence of the  50 B. J. Brandhuber, T. Boone, W. C. Kenny, D. B. McKay,
unfolding of proteins is often utilized as a method to provide       Three-dimensional  structure of interleukin-2,  Science,accelerated Stability studies. Although an increase in T   is                                                               1987, 238(4834), 1707-1709.often interpreted as an indication of increased protein stabil                                                        N. Byrne, L.-M. Wang, J.-P. Belieres, C. A. Angell, Revers
ity which sometimes correlates with an increased shelf life,        ible folding-unfolding, aggregation protection, and multi                                                                  55the fact that IL-2 melting was not fully reversible means that                                                            year stabilization, in high concentration protein Solutions,a direct correlation between the melting temperature and                                                             using ionic liquids. Chem. Commun. 2007, 2714-2716.conformational stability cannot be firmly established. The                                                         D. Constatinescu, C. Herrmann, H. Weingartner. Patterns ofshape of the unfolding transition does appear to indicate a                                                                   protein unfolding and protein aggregation in ionic liquids.cooperative  transition, but the plateau for pre-transition                                                                Phys. Chem. Chem. Phys. 2010, 12, 1756-1763.region is less defined than normally seen for a pure protein  60
and may indicate a heterogeneous population offolded struc     K. Fujita, D. R. MacFarlane, M. Forsyth, M. Yoshizawa
tures. An increase in T  indicates a possibility to thermody        Fujita, K. Murata, N. Nakamura, H. Ohno, Solubility and
namically stabilize IL-2 using CDHP as a formulation excipi         stability of cytochrome c in hydrated ionic liquids: Effect
ent, but the results also show that IL-2 is kinetically unstable      of oxo acid residues and kosmotropicity, Biomacromol
in that it readily aggregates upon unfolding/refolding similar  65    ecules 2007, 8, 2080-2086,
to that seen previously for IL-2 in 5% glucose, 10 mM    K. Fujita, M. Forsyth, D. R. MacFarlane, R. W. Reid, G. D.
NaOAc, pH 4.0 (Arakawa, 2001).                                        Elliott, Unexpected improvement in stability and utility of

---

## Page 42

US 9,289,381 B2
                 49                                       50
  cytochrome c by Solution in biocompatible ionic liquids,     cited herein are incorporated by reference in their entireties
  Biotechnology and Bioengineering 2006, 94(6), 1209     for the teachings relevant to the sentence and/or paragraph in
   1213.                                              which the reference is presented.
K. Fujita, D. R. MacFarlane, M. Forsyth, Protein Solubilising      That which is claimed is:
  and Stabilising Ionic Liquids, Chem. Commun. 2005,         1. A parenterally injectable pharmaceutical composition
  4804-4806.                                                comprising:
J. Geigert, N. Solli, P. Woehleke, S. Vemuri, Development and        (a) from 0.01 to 40 weight percent choline dihydrogen
   shelf-life determination of recombinant interleukin-2 (Pro         phosphate;
   leukin), in Stability and Characterization of Protein and        (b) an added base included in an amount not greater than 40
  Peptide Drugs Case Histories, Y. J. Wang, R. Pearlman,  10      weight percent, wherein said added base is choline
  Eds. Plenum Press: New York, 1993, pp. 249-263.                hydroxide:
A. Hedoux, F. Affouard, M. Descamps, Y. Guinet, L. Paccou,         (c) at least 60 weight percent water; and
  Microscopic description of protein thermostabilization        (d) from 0.01  to 10 weight percent active compound
  mechanisms with disaccharides from Raman spectroscopy          Selected from the group consisting of Interleukin-2,
   investigations,  J.  Phys.  Condens.  Matter 2007,  19.  15       gelsolin, antibodies, erythropoietin, interferon, human
  2O5142.                                                   growth hormone,  follicle stimulating hormone, and
D. Hekmat, D. Hebei, S. Joswig, M. Schmidt, D. Weuster         granulocyte colony stimulating factor;
   Botz, Advanced protein crystallization using water-soluble        said composition having a pH of from 6 up to 8:
   ionic liquids as crystallization additives, Biotechnol. Lett.        said composition packaged in a sterile container.
  2007, 29, 1703-1711.                                                2. The composition of claim 1, wherein said active com
B. Landgraf.  F. E. Cohen, K. A. Smith, R. Gadski, T. L.    pound is included in an amount of not more than 5 weight
   Ciardelli,  Structural  significance  of  the  C-terminal     percent.
  amphiphilic helix of interlekin-2, J.  Biol. Chem. 1989,        3. The composition of claim  1, wherein said water is
  264(2), 816-822.                                           included in an amount up to 99 weight percent.
D. R. MacFarlane, R. Vijayaraghavan, H. N. Ha, A. Izgoro  25     4. The composition of claim 1, wherein said choline dihy
   din, K. D. Weaver, G. D. Elliott, Ionic liquid “buffers’  pH    drogen phosphate is included in an amount of not more than
   control in ionic liquid systems, Chem. Comm. 2010, 46,    40 weight percent.
  7703-77.05.                                                           5. The composition of claim 1, wherein said base and said
D. S. Maclean, Q. Qian, C. R. Middaugh, Stabilization of     choline dihydrogen phosphate are included togetherina com
   proteins by low molecular weight multi-ions, J. Pharm.  30 bined amount not more than 50 weight percent.
   Sci. 2002, 91 (10), 2220-2229.                                          6. The composition of claim 1, wherein said composition is
S. B. Petersen, V. Jonson, P. Fojan, R. Wimmer, S. Pedersen,     a single phase liquid Solution.
   Sorbitol  prevents  the  self-aggregation  of  unfolded        7. The composition of claim 1, wherein said composition
  lysozyme leading to an up to 13° C. stabilization of the    has an osmolality of 100 to 3,000 milliOSmoles per kilogram
  folded form, J. Biotechnol. 2004, 114, 269-278.            35 of water.
S. Singh, J. Singh, Effect of Polyols on the conformational        8. The composition of claim 1, wherein said active com
   stability and  biological  activity of a  model  protein    pound is Interleukin-2.
  lysozyme, AAPS PharmSciTech. 2003, 4(3), Article 42.           9. The composition of claim 8, wherein said Interleukin-2
N. Sreerama, R. W. Woody, Estimation of protein secondary      is human Interleukin-2.
   structure from circular dichroism spectra: comparison of 40    10. The composition of claim 8, wherein said Interleukin-2
  CONTIN, SLECON, and CDSSTR methods with an      is aldesleukin.
  expanded reference set, Anal. Biochem. 2000, 287, 252        11. The composition of claim 1, wherein said active com
  26O.                                              pound is gelsolin.
R. Vijayaraghavan, A. IZgorodin, V. Ganesh, M. Surianaray        12. The composition of claim 11, wherein said gelsolin is
                                                               45 human gelsolin.  anan, D. R. MacFarlane, Long-term structural and chemi
   cal stability of DNA in hydrated ionic liquids, Angew        13. The composition of claim 1, wherein said active com
  Chem. Int. Ed. 2010, 49, 1631-1633.                     pound is recombinant.
R. M. Vrikkis, K.J. Fraser, K. Fujita, D. R. MacFarlane, G. D.        14. The composition of claim 1, wherein said active com
   Elliott, Biocompatible ionic liquids: A new approach for    pound is non-glycosylated.
   stabilizing proteins in liquid formulation, J. Biomech. Eng.  50    15. The composition of claim 1 having a shelf life of from
  2009, 131,074514.                                    2 days to 2 years at 37°C.
W. Wang, K. Antonsen, Y. J. Wang, D. Q. Wang, pH depen        16. The composition of claim 1, wherein said active com
  dent effect of glycosylation on protein stability, Eur: J.    pound is Interleukin-2 and said composition has a shelflife of
  Pharm. Sci. 2008, 22, 120-127.                          2 days to 2 months at 37°C.
L. Whitmore, B. A. Wallace, DICHROWEB, an online server  55    17. A method comprising administering a composition of
   for protein secondary structure analyses from circular     claim 1 to a subject in need thereof.
   spectroscopic data, Nucl. Acids Res. 2004, 32, W668        18. The composition of claim 1, wherein:
  W673.                                                          said active compound is included in an amount of not more
T. Yamada, A. Fujishima, K. Kawahara, K. Kato, O, Nish         than 5 weight percent;
  imura, Importance of disulfide linkage for constructing the  60    said water is included in an amount up to 99 weight per
  biologically active human interleukin-2, Arch. Biochem.           cent;
  Biophys. 1987, 257(1), 194-199.                                 said choline dihydrogen phosphate  is included  in an
  The foregoing is illustrative of the present invention, and is        amount of not more than 40 weight percent;
not to be construed as limiting thereof. The invention is        said base and said choline dihydrogen phosphate are
defined by the following claims, with equivalents of the  65      included together in a combined amount not more than
claims to be included therein. All publications, patent appli        50 weight percent;
cations, patents, patent publications, and other references        said composition is a single phase liquid solution;

---

## Page 43

US 9,289,381 B2
                  51                                       52
   said composition has an osmolality of 100 to 3,000 mil
    liOSmoles per kilogram of water, and
   said active agent is Interleukin-2.
   19. The composition of claim 1 having a shelf life of from
2 weeks to 2 years at 37°C.
  20. The composition of claim 1 having a shelflife of at least
2 weeks at 37° C.
  21. The composition of claim 1 having a shelflife of at least
1 month at 37° C.
  22. The composition of claim 1 having a shelflife of at least  10
1 year at 37° C.
  23. The composition of claim 1, further comprising from
0.01 to 50 weight percent of at least one osmolyte.
                                 k     k     k     k     k